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Abstract  11 
Biopharmaceuticals are increasingly important for patients and the pharmaceutical industry due to their 12 
ability to treat and, in some cases, even cure chronic and potentially life-threatening diseases. Most 13 
biopharmaceuticals are administered by injection, but intensive focus on development of systems for oral 14 
delivery of biopharmaceuticals may result in new treatment modalities to increase patient compliance and 15 
reduce product cost. 16 
In the preclinical development phase, use of experimental animal models is essential for evaluation of new 17 
formulation designs. In general, limited oral bioavailability of biopharmaceuticals, of just a few percent, is 18 
expected, and therefore, the animal models and the experimental settings must be chosen with outmost 19 
care. More knowledge and focus on this topic is highly needed, despite experience from the numerous 20 
studies evaluating animal models for oral drug delivery of small molecule drugs. This review highlights and 21 
discusses pros and cons of the most currently used animal models and settings, and in addition also the 22 
influence of anesthetics and sampling methods for evaluation of drug delivery systems for oral delivery of 23 
biopharmaceuticals primarily with examples on insulin. 24 
 25 
 26 
 27 
Keywords  28 
Peptides, proteins, insulin, in situ perfusion, in vivo, macromolecules 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
Abbreviations: API, active pharmaceutical ingredient; BE, bioequivalence; CLSM, confocal laser scanning microscopy; DDS, drug 48 
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emission computed tomography; TEM, transmission electron microscopy  54 
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1. Introduction 55 
During the last decades, biopharmaceuticals (e.g. peptides and proteins) have become a growing part of 56 
the pharmaceutical industry, and the drugs of choice for treatment of numerous chronic and potentially 57 
life-threatening diseases e.g. cancer, inflammatory diseases and diabetes [1,2]. At the time being, 58 
subcutaneous or intravenous administration of biopharmaceuticals is still the most widely used route of 59 
administration. Currently, approximately 100 biopharmaceutical drug compounds are on the market 60 
worldwide, and seven of these are in top 10 of the most selling drugs [3–6]. It is estimated that 61 
approximately 270 peptides are currently tested in clinical trials and more than 500 are in preclinical 62 
development [5]; numbers providing good indications towards a rapidly growing market. Oral delivery of 63 
drugs is the preferred route of dosing due to ease of administration, high patient convenience and thus, 64 
compliance and relatively low costs [6,7]. Desmopressin, a synthetic analogue of vasopressin, serves as a 65 
positive example of a marketed oral peptide drug formulation, along with promising results for oral delivery 66 
of semaglutide, a GLP-1 analogue. But despite these successes, there are many obstacles to deliver 67 
biopharmaceuticals in general via the oral route. Among those obstacles are the large molecular size of the 68 
drug together with their low stability in biological fluids, mainly caused by enzymatic degradation and low 69 
pH in the gastrointestinal (GI) environment. Moreover, biopharmaceuticals are known to have a low 70 
permeation across the intestinal mucosa [1,3,5,8–10], resulting in a very low bioavailability after oral dosing 71 
[11]. Due to the limited bioavailability, selection of the correct animal model and experimental settings are 72 
key elements when evaluating oral delivery of biopharmaceuticals and the appurtenant drug delivery 73 
systems (DDS). Furthermore, all experimental variables need to be assessed, including how they can 74 
potentially affect the readout of the experiment. A recent review by Sjögren et al. [12] addresses the 75 
importance of anatomy and physiology variability between various species when conducting animal 76 
studies. The aim of the present review is to give some guidelines when conducting animal studies, both in 77 
vivo, in situ and ex vivo, to assess the potential of oral DDS containing biopharmaceuticals. The models will 78 
be described and discussed including their respective advantages and disadvantages.  79 
In the following, ex vivo is defined as studies, where the organs are placed in an external environment, 80 
whereas in in situ studies, the organ is studied as a whole in the living animal. Furthermore, in vivo studies 81 
are described, when investigating the biopharmaceutical in the whole living animal. In addition, in vitro 82 
models, refers to experiments with cells or excised tissue outside their normal biological environment, and 83 
these will only briefly be described. For a more detailed review on in vitro models, the reader is referred to 84 
recent reviews [12,13]. In silico modelling will also only be briefly touched upon, as this is excellently 85 
addressed in a recent review [14]. 86 
 87 
2. Drug delivery system designs for oral delivery of biopharmaceuticals 88 
After almost 100 years of research within the area of oral delivery of biopharmaceuticals [10], more 89 
knowledge is still needed to succeed within this topic. As of today, the most promising attempts to succeed 90 
with oral delivery of biopharmaceuticals include a combination of enteric coating for delivery to the site of 91 
absorption. Moreover, addition of protease inhibitors and permeation enhancers to the DDS may enhance 92 
the absorption of the biopharmaceuticals through the intestinal membrane [10]. Novel approaches of 93 
utilizing e.g. microneedles in the GI tract may further facilitate the membrane transport [15]. These 94 
approaches optimally ensure delivery of an intact drug molecule at or into the surface of the intestinal 95 
membrane (the site of absorption), and the transport through the membrane. Delivery of intact and 96 
solubilized drug to the site of absorption is challenging due to varying pH in the GI tract, ranging from pH 1–97 
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2 in fasted stomach to pH of 5.5–6.5 in the duodenum, and pH 5.5–7.0 in the large intestine [6]. In both the 98 
stomach and intestine, numerous digestive enzymes are present together with an intestinal flora, the 99 
microbiota, providing a very unstable environment for the biopharmaceuticals [16]. By utilizing an enteric-100 
coated DDS for protection, it is possible to avoid degradation of the drug and have the biopharmaceutical 101 
to pass the stomach and reach the small intestine for absorption. Moreover, it is important to carefully 102 
consider the impact of the physicochemical properties, e.g. molecular weight, biophysical stability in the 103 
harsh GI environment, lipophilicity and ionization constant of the specific drug for the delivery potential. 104 
This needs to be assessed in relation to the biological barriers considering proteolysis in the stomach, 105 
variable pH values and poor permeation through the biological membranes, restricting the absorption from 106 
the GI tract. It is of course essential to ensure that the biological activity of the biopharmaceutical is 107 
maintained when developing an oral DDS [6,17]. The majority of ongoing research includes calcitonin and 108 
insulin as model drugs due to their frequent dosing and clinical importance thus, high economic impact [5]. 109 
In literature, a variety of in vivo, in situ and ex vivo models have been used involving various animal species, 110 
but also many different experimental settings have been utilized [12]. Table 1 and 2 provide an overview of 111 
the animal studies in literature with oral DDS for insulin (Table 1) and other biopharmaceuticals (Table 2). 112 
 113 
3. Barriers to overcome for successful oral delivery 114 
Apart from preventing degradation, a main obstacle for successful oral delivery of biopharmaceuticals is 115 
the limited permeation across the intestinal membrane (Figure 1). Thus, researchers aim to increase the 116 
permeation across the biological membrane by various means [3,8,10]. Often, the complexity and 117 
variability of the gut physiology and the influence that this may have on absorption is underestimated, 118 
when designing DDS to be absorbed from the small intestine. It is essential to include animal studies in the 119 
early development phase in order to integrate the dynamic processes happening simultaneously in the 120 
body, whereby the iterative design process towards an optimized DDS will have a greater chance of success 121 
[18]. Two major determinants for successful absorption from the GI tract are dissolution and permeation, 122 
and as biopharmaceuticals are generally freely soluble in aqueous medium with a logP value <0 dissolution 123 
will usually not be the rate-limiting step [19,20]. It can therefore be useful to assess the membrane 124 
permeability to the given biopharmaceutical in vitro before moving to animal models. Examples of in vitro 125 
permeability experiments include use of excised tissue, cultured cells, artificial membranes and isolated 126 
mucosal cells [18,19]. Following positive in vitro permeability results, it is essential to perform animal 127 
studies. When selecting an animal model, it is important to keep in mind the impact of the anatomical and 128 
the physiological differences and similarities between and within species. Even though, the morphology of 129 
the intestinal membrane may be seen as comparable in broad terms across species, drug transporter 130 
proteins, intestinal metabolizing enzymes, microorganisms, fluid volume and flow, and concentrations of 131 
intestinal secretions can differ from species to species, which is crucial to keep in mind [18]. Furthermore, 132 
pH values in the stomach and intestine may also differ from the animal in comparison to humans, and the 133 
total absorptive area of the intestine is different [12]. In addition, the physiology of the intestine will 134 
change with age, and will thus, be different in children and in the elderly population compared to middle-135 
aged adults. This review does not go into depth with the differences in GI physiology, and how it will 136 
influence the permeability of intestinal mucosa to oral biopharmaceuticals.  137 
 138 
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 139 
Figure 1: Graphic showing the in vivo barriers in the intestine following oral administration.140 
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Table 1: Overview of studies evaluating oral delivery of insulin in animals 
Administration route Specie Blood sampling Quantification method  References 
Colonic injection  Rats, diabetic Portal vein Blood glucose [21] 
Duodenal administration Rats Jugular vein Blood glucose, ELISA and radioimmunoassay [7,22–25]  
Duodenal cannulation Rats, diabetic Carotid artery Blood glucose [26] 
Duodenal cannulation Rabbits Carotid artery Blood glucose [27] 
Ex vivo ileum Rabbits N.S. Papp via HPLC [28,29] 
Ex vivo ileum Sheep N.S. Papp via HPLC [29] 
Ex vivo jejunum Sheep N.S. Histology test [29] 
Ex vivo jejunum, duodenum and ileum Rats N.S. HPLC and CLSM [30–32] 
Ex vivo jejunum and colon Rats N.S. Lactate dehydrogenase assay [33] 
Ex vivo permeation of colon Rats, diabetic N.S. HPLC [21] 
In situ duodenal and ileal loop Rabbits, diabetic Jugular vein Blood glucose [34] 
 
In situ ileal loop perfusion       Rats Caudal vein Blood glucose [35]
In situ isolated intestinal loop Rats, diabetic N.S. Histology of follicular mucosa (Peyer’s patches) up to 
4 h using fluorescence microscopy 
[36] 
In situ jejunum, ileum and colon Rabbits Mesenteric 
vein  
Radioimmunoassay  [34] 
In situ single pass perfusion  Rats N.S. HPLC [37] 
 Rats Jugular vein Blood glucose, ELISA, PET imaging 
PET imaging and ELISA 
[28,38–41] 
 
Intestinal loop (injection) Rats N.S. Fluorescence microscopy [31,42,43] 
Intraduodenal injection Rats, diabetic Tail vein Blood glucose, enzyme immunoassay kit and blood 
glucose 
[44–46] 
Intraduodenal injection Rats, diabetic N.S. Blood glucose [47] 
Intragastric injection Rats Tail vein Blood glucose [48–50] 
Intragastric gavage Rats, diabetic Eye Glucose oxidase and plasma glucose [51] 
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Table 1. Continued. 
Administration route Specie Blood sampling Quantification method  References 
Intragastric gavage Rats, diabetic  Tail vein Blood glucose and ELISA [52–54] 
Intragastric gavage Rats, diabetic  Tail vein Blood glucose and HPLC [55] 
Intragastric gavage Rats, diabetic  Leg vein Blood glucose and ELISA [56] 
Intragastric gavage Rats, diabetic  Eye Blood glucose and ELISA [57] 
Intragastric injection Rats, diabetic Tail vein Blood glucose [50] 
Intragastric injection Mice, diabetic Tail vein Blood glucose and ELISA [58] 
Intragastric placement  Pigs Femoral vein Blood glucose, ELISA and radiographs  [15] 
Intraileal injection Rats Tail vein Blood glucose [59] 
Intrajejunal administration Rats Tail or jugular vein Blood glucose, ELISA and histology [60] 
Intrajejunal injection Mice Tail vein ELISA [61] 
Intrajejunum injection Pigs Descending aorta Blood glucose and ELISA [62]  
Oral administration (tablet, deep in the 
throat) 
Mice, diabetic Eye Blood glucose [63,64] 
Oral administration (tablet, deep in the 
throat)  
Rats Tail vein Blood glucose and ELISA [65–69]  
Oral administration (tablet) Rats, diabetic Tail vein Blood glucose and ELISA [70] 
Oral gavage (capsules) Rats, diabetic  Tail vein Blood glucose and ELISA [71–77] 
Oral gavage (capsules) Rats, diabetic N.S.  Blood glucose [78] 
Oral gavage (capsules) Rats Tail vein Blood glucose and ELISA [30,59,79,8
0] 
Oral gavage (capsules) Rats, diabetic Eye Blood glucose, histology and mucoadhesion [81] 
Oral gavage (capsules) Rabbits N.S. ELISA [82] 
Oral gavage of hydrogel Rats, diabetic N.S. Blood glucose [83] 
Oral gavage of suspension Mice, diabetic Tail vein Blood glucose [84–86]  
Oral gavage of suspension Mice, diabetic Eye Blood glucose and ELISA [87,88] 
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Table 1. Continued. 
Oral gavage of suspension Mice Tail vein Blood glucose and ELISA [61,85,89] 
Oral gavage of suspension Rats, diabetic  Eye  Blood glucose, peroxidase, radioimmunoassay, ELISA 
and CLSM 
[33,51,90–
104] 
Oral gavage of suspension Rats, diabetic  Tail vein Blood glucose, ELISA and SPECT/CT [24,31,36,4
2,43,72,77,
105–125]  
Oral gavage of suspension Rats, diabetic Femoral artery Blood glucose and ELISA [126] 
Oral gavage of suspension Rats Eye Blood glucose and ELISA [127] 
Oral gavage of suspension Rats Tail vein Blood glucose, ELISA, imaging and HPLC [27,106,12
4,128–130] 
Oral gavage of suspension Rats, diabetic N.S. Fluorescence microscopy, CLSM, blood glucose and 
ELISA  
[54,57,131,
132] 
Oral gavage of suspension Rats N.S. CLSM  [111] 
Oral gavage of suspension Rats Subclavian vein Blood glucose and radioimmunoassay [88,133] 
Oral gavage of suspension Dogs, diabetic Jugular vein Blood glucose [134] 
Oral gavage of suspension Rabbits  Radioimmunoassay [29] 
Oral gavage of suspension Rabbits, diabetic Ear vein  Blood glucose [135] 
Oral gavage of suspension Mice  Imaging via eXplore Optix system [136]  
Oral gavage of suspension Mice, diabetic Eye Blood glucose [136] 
 
  
Administration route Specie Blood sampling Quantification method  References 
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Table 2. Overview of studies evaluating oral delivery of biopharmaceuticals (except for insulin) in animals. 
Biopharmaceutical Administration route Specie Blood sampling Quantification method  References 
Antihypertensive 
peptide (Val-Leu-Pro-
Val-Pro-Arg) 
Oral gavage of suspension  Rats, 
hypertensive 
N/A Blood pressure by the tail cuff method [137] 
Antide Oral administration (tablet, 
deep in the throat) 
Rats Tail vein LC-MS of plasma [138] 
Buserelin Intraduodenal injection Rats Carotid artery Radioimmunoassay [139] 
Exendin-4 In situ perfusion  Rats Heart puncture Immunoassay kit [35,140]  
Exendin-4 In situ perfusion Rats N.S. Fluorescence microscopy [141] 
Exendin-4 Intraintestinal injection  Mice, diabetic Tail vein Blood glucose [141] 
GLP1 Jejunal placement  Rats Tail vein Blood glucose [49] 
GLP1 Oral gavage of suspension Mice N.S. Blood glucose [142] 
GLP1 Oral gavage of suspension Mice, diabetic Tail vein Radioimmunoassay, intraperitoneal 
glucose tolerance test, blood glucose, 
near-infrared imaging and X-ray 
[143,144] 
GLP1 Oral gavage of suspension Rats Jugular vein, carotid 
artery and eye 
ELISA [143,145] 
GLP1 Oral gavage of suspension Rats, diabetic Tail vein Blood glucose, ELISA and pancreatic 
insulin after euthanisation 
[146,147] 
Granulocyte 
colony-stimulating 
factor  
Oral gavage of suspension Rats Tail vein ELISA [148] 
Heparin (conjugate) Oral gavage of suspension Mice Heart puncture Anti-factor assay kit [149] 
Leuprolide Ex vivo, intestine Rabbits N.S. Radioimmunoassay [150] 
Leuprolide Intrajejunum, intraileum or 
intracolonic injection 
Rats Portal vein and aortic 
artery 
Radioimmunoassay [150] 
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Table 2. Continued 
Biopharmaceutical Administration route Specie Blood sampling Quantification method  References 
Leuprolide Oral administration (tablet, 
deep in the throat) 
Rats Tail vein LC-MS of plasma [151] 
Leuprolide Oral gavage of suspension Rats Tail vein LC-MS of plasma [11] 
Myrcludex B Oral gavage of suspension Rats Sacrificed Radioactive liver count [152] 
Protein Alpha 
crystallin 
Oral gavage of suspension Mice Eye ELISA [153] 
Salmon calcitonin Ex vivo, intestine Rats Retroorbital Fluorescence spectroscopy, ELISA and 
histology 
[154] 
Salmon calcitonin In situ single pass perfusion Dogs Portal vein Radioimmunoassay [155] 
Salmon calcitonin Intraduodenal injection Rats Tail vein  ELISA  [156] 
Salmon calcitonin Intraduodenal injection Rats Eye Colorimetric calcium by UV 
spectrophotometer 
[26] 
Salmon calcitonin Intrajejunal injection Rats Tail vein  ELISA  [157] 
Salmon calcitonin Intrajejunal injection Rats Heart puncture Colorimetric method [158] 
Salmon calcitonin Intrajejunal injection Rats Jugular vein ELISA [159] 
Salmon calcitonin Oral administration (tablet, 
deep in the throat) 
Rats Tail vein Chromogenic assay  [160] 
Salmon calcitonin Oral gavage (capsules) Rats Jugular vein Photometry, radioimmunoassay and [155,161]  
Salmon calcitonin Oral gavage (capsules) Rats Tail vein milking ELISA [157] 
Salmon calcitonin Oral gavage of suspension  Rats Intestinal tissue CLSM and fluorescence [162,163]  
Salmon calcitonin Oral gavage of suspension Rats Jugular vein Calcium assay [163,164] 
Salmon calcitonin Oral gavage of suspension Rats Saphenous vein Calcium assay [165–167] 
Salmon calcitonin Oral gavage of suspension Rats Tail vein Calcium assay, colorimetric method 
and ELISA 
[168–172] 
 11 
Abbreviations used in the tables: CLSM: Confocal laser scanning microscopy, ELISA: enzyme-linked immunosorbent assay, HPLC: High-performance liquid chromatography, LC-MS: Liquid 
chromatography–mass spectrometry, N/A: Not applicable, N.S.: Not stated, UV: ultra-violet.  
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4. Ex vivo and in situ models 1 
Ex vivo models refer to experiments in live animals with the organs placed in external environments 2 
ensuring lowest possible change in native conditions. Similar to studies with ex vivo models, in situ models 3 
may also be used and has the advantage that the whole organ is studied intact in a living animal (Table 3). 4 
Ex vivo and in situ studies count for 14 and 11 % of the total number of conducted animal studies, for 5 
studies with insulin (Figure 2A) and other biopharmaceuticals, respectively (Figure 2B) (information from 6 
Table 1 and 2). In Figure 2, the in situ studies and intestinal administration have been divided into two 7 
columns, these can be similar investigations, but the intestinal administration refers to either injection or 8 
placement of the DDS in the intestine, whereas the in situ studies describes investigations utilizing a flow of 9 
medium through the intestinal segment(s). In situ perfusion of intestinal segments in the GI tract of rodent, 10 
typically rats or alternatively rabbits, are frequently used to study the permeation and absorption kinetics 11 
of drugs. Under those experimental settings, intestinal segments can be cannulated and the drug 12 
formulation in solution or suspension with or without DDS can be flushed through the isolated intestinal 13 
section. This procedure is referred to as the single-pass perfusion model, but as an alternative is the 14 
Doluisio approach, a closed-loop model, where the intestinal segment is filled with the solution or 15 
suspension throughout the entire experiment [173,174]. Both models have shown to provide intestinal 16 
membrane permeability values correlating closely to human data for small molecules [173]. The biggest 17 
advantage of the in situ methods compared to in vitro techniques is the presence of an intact blood and 18 
nerve supply in the live animals [18]. Rat and human jejunum effective permeability estimates of passively 19 
absorbed drugs in solution correlate highly for small molecules, and both can be used with precision to 20 
predict in vivo oral absorption of such drugs in man [175].  21 
An advantage with in situ perfusion studies is that the whole intestine can be perfused or merely selected 22 
small segments, depending on which investigations are initiated. The predictability of the rat in situ 23 
perfusion model appears to be useful for the prediction of active uptake in humans, as rats have similar 24 
patterns of expression of the small intestinal membrane transporters as humans [176]. A recent study used 25 
in situ closed intestinal loops in rats to identify the region-dependent effect of potential absorption 26 
enhancers, penetratin and penetramax, indented for oral delivery of insulin [40]. The intestinal segments 27 
studied were duodenum, jejunum, ileum and colon, and test solutions were administered directly to the 28 
loop segments 30 min after surgery. The experiment concluded that ileum and colon appeared to be the 29 
most effective target sites for the tested permeation enhancers, as explained by the higher level of 30 
protease activity in the upper small intestine [40]. In the same study, it was shown that the maximal 31 
absorption detected depended on the enhancer used. Carrier peptides are used in some studies as 32 
intestinal absorption enhancers in combination with for example insulin, and for e.g. L-penetratin, the most 33 
pronounced effect was observed in the ileum, followed by jejunum, duodenum and colon. In contrast, D-34 
penetratin resulted in the highest blood concentrations of insulin after dosing in the colon, and less after 35 
dosing in the duodenum, jejunum and then ileum, respectively [40]. Thus, due to such DDS dependent 36 
regional differences, it seems that no general recommendation is clear regarding which region to 37 
administer the formulation to. In general, knowledge of GI regional differences related to intestinal drug 38 
absorption and effect on the specific evaluated DDS is crucial when setting up an animal experiment. A 39 
recent review focused on the intestinal absorption pathways of insulin nanoparticles in animal models 40 
[177]. That review concluded that intestinal absorption of insulin-loaded nanoparticles is closely related to 41 
accumulation of the particles in Peyer’s patches, primarily located in the distal ileum [178], whereas the 42 
pathway of delivery for DDS targeting enterocytes and/or tight junctions remains unclear [177].  43 
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Ex vivo models are also utilized to investigate membrane permeation of the biopharmaceutical and/or 44 
interaction of the DDS with the intestinal membrane. A subcategory of ex vivo models is ex situ models, 45 
where organisms are moved from their natural environment. Often used models in relation to studies on 46 
oral delivery of biopharmaceuticals are ex situ barrier models assessing transport of compounds across 47 
excised intestinal tissue. The use of Ussing chambers to predict oral absorption has previously been 48 
reviewed, and the reader is referred to those excellent reviews for more details on the experimental setup 49 
[18,179,180]. In the reviews by Sjögren et al. [12] and Lennernäs [179], it is highlighted that more 50 
knowledge is needed from such ex vivo studies especially regarding the regional intestinal effective 51 
permeation to form the basis of improved in silico models [179]. Since the publication of those reviews, a 52 
study has evaluated the permeation of fluorescein isothiocyanate (FITC)-labelled insulin ex vivo using fresh 53 
rat ileum mucosal tissue and compared the findings to in vitro data from Caco-2/HT-29-MTX-E12 cell co-54 
cultures [181]. The study showed that the apparent membrane permeability (Papp) of insulin dosed in 55 
trimethyl chitosan nanoparticles was 1.34-fold higher compared to unmodified nanoparticles and 1.87-fold 56 
increased as compared to the use of micelles [181]. When comparing with in vitro data, the same trend was 57 
observed both with and without the presence of mucus (e.g. 1.10 vs. 1.16-fold increase with mucus and 58 
1.14 vs. 1.23-fold increase without mucus). Last, the study evaluated the DDS in animal studies after oral 59 
administration to diabetic rats. The blood glucose depression as observed 3 h after administration was 60 
found to be decreased 1.28-fold when comparing trimethyl chitosan nanoparticles to unmodified 61 
nanoparticles, whereas the decrease was 1.62-fold when comparing trimethyl chitosan nanoparticles to 62 
micelles [181]. Thus, all three models showed the same ranking of the formulations despite more 63 
pronounced difference between the formulations in the in vitro experiment than in the in vivo study. How 64 
those data and thus models are related to efficacy studies in man is yet to be addressed. 65 
L-valine-appended PLGA particles for oral delivery of insulin has been studied using an ex vivo everted 66 
intestine method and applied complimentary to oral gavage administration to diabetic rabbits [182,183]. 67 
The ex vivo data showed 48 % insulin transport across the intestine for PLGA particles compared to 91 % for 68 
L-valine-appended PLGA after 60 min. When tested in an animal model, the L-valine-appended PLGA 69 
showed a slightly sustained hypoglycemic response compared to the non-conjugated particles [183]. Those 70 
findings highlight the complexity of relating ex vivo data to in vivo findings. A more complex barrier must be 71 
overcome when administering a formulation orally compared to studying permeation across tissue ex vivo, 72 
resulting in a less pronounced difference between the DDS tested. Despite the advantage of using animal 73 
tissue with functional cells acting as a barrier for drug uptake, such experiments are time consuming to set 74 
up, but can be useful for screening and comparing DDS containing the same biopharmaceutical and 75 
beneficial to perform prior to in vivo studies [18].  76 
 77 
  
 78 
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79 
Figure 2: Overview of methods used to evaluate oral bioavailability of insulin (A) and other 80 
biopharmaceuticals (B) in vivo, ex vivo and in situ based on reviewed papers listed in Table 1 and 2.  81 
 82 
Table 3: Overview of the pros and cons of the most used animal models for testing oral biopharmaceuticals  83 
Model Aim Pros Cons 
Ex vivo Permeation and 
absorption kinetics  
Regional differences can 
be investigated 
 
Organisms are taken out of 
the animal 
In situ Permeation and 
absorption kinetics  
Regional differences can 
be investigated. 
Permeability data similar 
to human data 
No data on passing through 
the stomach 
In silico Mechanistic or 
physiology-based 
pharmaceokinetic 
simulations 
Does not include animals Does not include in vivo 
solubility, stability and 
metabolism  
In vivo, healthy 
animals 
Oral PK, PD and 
bioavailability 
evaluation 
Better animal welfare Not conclusive to in 
regards to disease 
treatment 
In vivo, diseased 
animals 
Oral PK, PD, and 
bioavailability 
evaluation in diseased 
animals  
Might be a more realistic 
scenario to the human 
situation 
Large variations in the 
animal disease and 
translation of data to man 
 84 
5. In silico models 85 
In silico approaches refer to computer simulations, ranging from applying simple rules to advanced dynamic 86 
modelling [18]. Modelling of compound solubility and membrane permeability plays an increasingly 87 
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important role in drug discovery as they can be used as tools for early parameterization of mechanistic or 88 
physiology-based pharmacokinetic models or as starting points for refined models of a constrained series 89 
of chemical analogues [19,184]. Recently, in silico modelling has also been shown to be a useful tool to 90 
screen for new permeation enhancers and optimization of the physicochemical aspects of surfactant 91 
enhancer systems for oral delivery of proteins [185]. This study utilized a Random Forest Quantitative 92 
Structural Activity Relationship (QSAR) model, which was validated based on drug permeation data 93 
obtained from studies in Caco-2 cell culture models [185]. It was concluded that this approach serves as a 94 
robust strategy to systematically assess novel enhancers, but cannot, however, stand alone in the selection 95 
process. As for biopharmaceutical delivery, it is important to emphasize that the model as of today does 96 
not include aforementioned important parameters such as solubility, stability and metabolism [185]. A 97 
recent and very thorough review did, however, conclude that computational biopharmaceutical profiling is 98 
useful for early prediction of drug delivery strategies [14]. For more information on computational 99 
prediction, the reader is referred to this review [14]. 100 
Several commercial software for advanced in silico modelling are available, and three of the most 101 
commonly used, Simcyp 13.3, GastroPlus 8.0 and GI-Sim 4.1, were recently compared in relation to their 102 
capability to predict human intestinal drug absorption [186]. The study used a priori modelling with input 103 
data from 12 poorly water soluble drugs, all characterized by incomplete gastrointestinal absorption. It was 104 
concluded that the three types of software, all provide useful guidance in formulation development, with 105 
GI-Sim and GastroPlus favored over Simcyp due to better prediction of intestinal absorption of 106 
incompletely absorbed drugs [186]. Due to the black box nature of in silico software, it is generally 107 
recommended always to use several models to assess the same problem [12,187]. Moreover, it is very 108 
challenging to utilize for biopharmaceuticals due to the complicated degradation kinetics in lumen and 109 
during permeation. A highly important aspect to note is that accurate determinations of effective 110 
permeability (Peff) is needed to serve as a basis for future in silico predictions of oral delivery of 111 
biopharmaceuticals [12]. Moreover, it should be emphasized that the current in silico models does not 112 
include the complex nature of the in vivo environments determining the dissolution behavior [188].  113 
 114 
6. In vivo models 115 
In vivo models comprise the use of living species and in these cases a biopharmaceutical or DDS (containing 116 
a biopharmaceutical) are dosed and the effect is tested after appropriate sampling and/or testing. The use 117 
of reproducible and reliable in vivo models is highly important and required for development and 118 
marketing of drugs for oral administration. Biopharmaceuticals are, due to previously described 119 
physicochemical properties, characterized by a poor absorption across intestinal epithelium resulting in a 120 
very low oral bioavailability, but results from in vivo studies highly can depend on the species used [11]. As 121 
previously mentioned, it is therefore crucial to utilize a highly sensitive and reproducible model, in order to 122 
be able to detect the relatively low changes in pharmacokinetic and pharmacodynamics parameters 123 
relating to increased oral bioavailability. Additionally, knowledge about how experimental conditions such 124 
as specie morphology, dosing method, anesthesia, sampling method, use of animal disease models 125 
resembling human diseases and finally choice of analytical method for sample evaluation is of great 126 
importance and will be discussed in the following sections.  127 
 128 
6.1. Use of animal models with or without human disease symptoms and choice of specie 129 
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One of the first choices to take when conducting animal studies is which specie to choose, and as seen from 130 
Figure 3, rats are used in 80 % of the studies listed in Table 1 and 2. Mice represent another species often 131 
chosen, used in 11 % of the insulin studies and in 16 % of studies with other biopharmaceuticals. The 132 
physiological variations among species were recently reviewed [12], for which reason we will not go into 133 
detail with this topic, but rather focus on practical considerations when setting up an animal model. As rats 134 
are the most commonly used species in this context, it is important to know the basic differences compared 135 
to humans. The GI tract of a rat differs from that of man in several ways with the absence of gall bladder, 136 
higher nocturnal activity and different gut flora in the rat. In general, rats appear to provide good estimates 137 
for the prediction of absorption for compounds without dissolution problems such as biopharmaceuticals, 138 
and also highly reflect the human mucosal barrier in the intestine. Despite this, metabolic differences often 139 
lead to misleading predictions of oral bioavailability in humans [18,19].  140 
Generally, when deciding on which animal model to apply, it is important to acknowledge that the 141 
bioavailability of biopharmaceuticals will be low even when avoiding the stomach and dosing directly to a 142 
specific part of the GI tract, due to enzymatic degradation and poor membrane permeability of large 143 
molecules. Bioavailability is, however, found to be slightly higher when drugs are administered directly to 144 
the jejunum as compared to other segments of the intestine [5]. One aspect is the low apparent 145 
bioavailability; another is the correlation to humans. A comprehensive study compared the absorption of a 146 
whole range of small molecule drugs after dosing to the intestine [176]. The study showed that almost no 147 
overall correlation exists between oral bioavailability in rat and human (r2=0.29), whereas a correlation 148 
exists for intestinal permeability (r2=0.8), both when considering carrier-mediated transport as well as 149 
passive diffusion mechanisms [176]. When evaluating the expression level of transporters in duodenum, a 150 
moderate correlation (r2=0.56) exists between rat and human [176].  151 
Another aspect to consider is whether to use animal models of human disease or healthy animals. Often 152 
the complexity and variability of gut physiology is underestimated, with only one or two variables being 153 
considered, this can either be in dosage form design or drug targeting approach [189]. Although strides 154 
have been made towards understanding the conditions and mechanisms responsible for absorption from a 155 
healthy gut, knowledge in this field is not yet complete. Even more significant is the lack of understanding 156 
the GI environment in the diseased state. Functionalized dosage forms cannot be evaluated in a 157 
reproducible manner without a comprehensive understanding of the conditions to which they are 158 
subjected during in vivo testing. Understanding and taking into account the intestinal environment will not 159 
only open up for improved evaluation of new dosage form designs, but also improve experimental settings 160 
for in vitro and pre-clinical tests in animal models leading to better in vitro in vivo correlations (IVIVC), and 161 
thus, opening new avenues for oral DDS for biopharmaceuticals [189].  162 
When reviewing the existing literature (Figure 3), 63 % of the studies administering insulin (Table 1) have 163 
included use of animal models of human diseases, whereas this is only the case for 14 % of non-insulin 164 
biopharmaceuticals (Table 2). The overall purpose of insulin administration is to replace the partly or 165 
complete lack of insulin in diabetic patients to prevent hyperglycemia [190]. Therefore, animal models of 166 
human diseases, in this case diabetic animals, are commonly used in order to gain insight of the efficacy of 167 
the administered DDS, eventually combined with knowledge of the mechanistic behavior of DDS [191].  168 
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169 
Figure 3: Overview of species used to evaluate oral bioavailability of insulin (A) and other 170 
biopharmaceuticals (B) in vivo, in situ or ex vivo. The data are based on reviewed papers, listed in Table 1 171 
and 2.   172 
 173 
Numerous diabetic animal models exist, ranging from type 1 diabetic with spontaneously developing 174 
autoimmune diabetes, chemical ablation of pancreatic β-cells to type 2 diabetic models, where both obese 175 
and non-obese animals are included. Moreover, transgenic and knockout mouse models are also used 176 
within diabetic research [190,192]. In the reviewed papers (Table 1), the most commonly used diabetic 177 
model is streptozotocin-induced diabetes in rats or mice, done by single intraperitoneal injection of 40-60 178 
mg/kg streptozotocin to rats [77,124] or 65-150 mg/kg to mice [84,87] destroying the pancreatic β-cells 179 
[193]. The animals are considered diabetic once the plasma glucose level reaches ≥ 250 mg/dL for rats [77] 180 
and ≥ 300 mg/dL to 400 mg/dL for fasted (12 h) and fed mice [84,87]. Unfortunately, streptozotocin does 181 
not only harm the pancreatic β-cells [194], but also causes renal injury together with oxidative stress 182 
inflammation and endothelial dysfunction [195], which may influence the readout. Thus, as there are pros 183 
and cons associated with the various animal models and induction of human diseases in these, careful 184 
consideration should be taken to select animal model(s) representing the physiological diversity seen 185 
among human diabetic patients [191]. Animal disease models seldom copy all the aspects of the 186 
corresponding human disease, and are less characterized in the toxicology area compared to healthy 187 
animals. For securing this, several reviews suggests that more than one animal model of human disease 188 
should be included in the studies [190,192,196]. However, the exact same aspect of heterogeneity in 189 
diabetic expression and complications hereof considerably challenges data evaluation from animal studies, 190 
as it might be problematic to separate the drug-induced effect from disease-related complications [191]. 191 
Besides the always relevant discussion regarding the use of diseased animal models, it has been discussed 192 
that different species and strains behave differently both in relation to induction of diabetes and during 193 
treatment hereof [190]. In general, animal models cannot observe the differences seen between diabetic 194 
men and women when looking into for example cardiovascular complications [196]. Moreover, animals of 195 
different gender e.g. for diabetic rats, might also respond differently to experimentally induced stress and 196 
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other metabolic variations, thus leading to gender-biased results. This is not seen in the same way for 197 
humans, but can influence the results of the animal studies substantially [190,196].  198 
 199 
No clear answer exists to the question of whether to use healthy or diseased animal models. Nonetheless, 200 
many caveats are associated with the use of animal models of human disease for assessment of oral DDS, 201 
when evaluating biopharmaceuticals with a known mode of action. Also, the animal welfare in terms of the 202 
complications associated with models of human diseases such as lack of histology control, diversity in 203 
disease expression leading to inclusion of more than one model of human disease, decreased life span and 204 
disease-related complications must be carefully considered [191,192].  205 
In terms of species, healthy animals such as Sprague-Dawley rats, CD-1 mice, Beagle dogs, cynomolgus 206 
monkeys and mini pigs are the most commonly used models for evaluation of small molecule drugs due to 207 
good homogeneity [191]. For biopharmaceuticals, however, a more pronounced species specificity exists 208 
[191], as certain biopharmaceuticals are only active when administered to humans or chimpanzees and in 209 
other cases immunogenicity hampers full assessment in some species [197]. Such cases and alternative 210 
strategies to address such challenges have been thoroughly reviewed previously, for this reason the reader 211 
is referred here for further information [197]. 212 
 213 
6.2. Effect of anesthesia on the readout 214 
Despite common knowledge in the scientific community of the fact that anesthesia is likely to affect the 215 
desired readout in animal models, not much literature exists addressing this aspect. When evaluating blood 216 
pressure, it is known that determination hereof is easier and with more accurate results when 217 
anaesthetizing the animals [198]. Contrary, anesthesia also introduces a significant variable, as it alters the 218 
blood pressure and cardiovascular reflexes among other physiological parameters [198].  219 
It has been discussed from an animal welfare perspective and also from a scientific validity perspective 220 
within the area of musculoskeletal research that standard protocols for anesthesia and pain management 221 
should be developed and applied for animal models [199]. A study from 1983 shows that intraperitoneal 222 
injection of pentobarbital to healthy rats increases the blood glucose level by 33 % already 3 min after 223 
administration, and returns to normal level only after 40 min [200]. Figure 4 depicts the effect on blood 224 
glucose level following subcutaneous (SC) administration of insulin to healthy male Sprague Dawley rats 225 
anaesthetized using the most commonly used anesthetics for such studies. The experiments were 226 
conducted after 12 h. 227 
 228 
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 229 
Figure 4: Effect of anesthesia on blood glucose level in healthy rats after subcutaneous (SC) dosing of 230 
insulin. The black arrows indicate momentary inhalation of isoflurane. The curves represent the average of 231 
three rats ± SEM, except for the negative control where n=1. Blood samples were collected via the 232 
sublingual tongue vein. 233 
 234 
The data depicted in Figure 4 clearly shows that a combination of ketamine/xylazine significantly decreases 235 
the blood glucose level, which is highly problematic if evaluating the unbiased effect of orally administered 236 
insulin. Fentanyl/midazolam does not have the same pronounced effect, but still results in a different 237 
profile as compared to non-anesthetized animals. More precisely, the maximum effect on the blood 238 
glucose level following insulin administration is delayed 60 min in the anaesthetized rats when compared to 239 
non-anaesthetized rats, and the recovery period is likewise significantly prolonged. It could be speculated, 240 
however, that the reduced recovery period in the non-anesthetized animals when compared to the 241 
anaesthetized animals is not only related to the effect of anesthesia, but also the blood sampling 242 
procedure. Thus, blood collection via the sublingual tongue causes a stress-induced elevated blood glucose 243 
level. Having said that, the authors experienced no sign of stress during handling in terms of diarrhea, urine 244 
excretion, screaming, fear of handling upon repeated blood sampling etc., which was the case when 245 
repeating the experiment using a restrainer. Conclusively, the effect of anesthesia is the most plausible 246 
explanation for variation in blood glucose level.  247 
In the negative control group, the rats were subjected to momentary inhalation of isoflurane (shown by 248 
black arrows in Figure 4), and this is shown to increase the blood glucose level, similar to the previously 249 
described effect of pentobarbital [200].  250 
Summing up, unless the selected animal model requires rigid restraint or if it is unethical from an animal 251 
welfare perspective due to the burden applied to the animal in conscious state after e.g. surgery, it is 252 
favored to use conscious models to avoid the impact from anesthesia [198]. Having said that, the stress 253 
applied to animals during surgeries such as cannulation of the intestine affects the animal for up to four 254 
days after surgery, and therefore, a recovery period of one week is highly recommended before conducting 255 
the experiment. 256 
 257 
6.3. Routes of administration and practical considerations 258 
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Choosing the optimal administration route to the animal models requires careful considerations in order to 259 
minimize the risk of potential adverse events [201]. Some of the aspects to be considered include the 260 
expertise or training required for successful administration, the volume or size of the dosage form needed 261 
for administration of a sufficient dose, the precise administration site, pH of the test sample and to which 262 
extent animal restraint is needed [201]. When evaluating the effect of orally administered DDS for delivery 263 
of biopharmaceuticals, the most frequently used dosing method is by far oral gavage (Table 1 and 2, Figure 264 
3).  265 
Oral gavage, mimicking the intended route of administration to humans, requires restraint of the animals 266 
and correspondingly moderate training of the research personnel [201]. It has been shown that such 267 
restrain induces increase in both blood pressure and heart rate for up to 1 h following the dosing with 268 
gavage together with an increased stress level for the animals [202]. This can, however, be significantly 269 
reduced if practicing the procedure with the animals in advance. For mice, the stress level is already 270 
normalized on the second day of training [202], whereas rats requires three training days to maintain 271 
normal heart rate and blood pressure during oral gavage [203]. Besides proper training, the stress level 272 
associated with oral gavage can be decreased by dipping the gavage device in sucrose before dosing [202]. 273 
This is, however, not recommended when evaluating compounds such as insulin and GLP-1, where blood 274 
glucose level can be the desired readout. Also, soft gavage tubes are favored over stainless steel, as it 275 
induces less stress to the animals. Although, a drawback of using soft tubes is the risk of the animals biting 276 
the tubes causing even more stress to the animals and potentially exclude the animal from the experiment 277 
[201]. Another important aspect to consider is the dosing volume, which is not recommended to exceed 5 278 
mL/kg. Larger volumes are likely to induce passive reflux, aspiration pneumonia, irritation in or even 279 
rupture of the GI tract [201,204] together with gastric distension, as rodents are not able to vomit [201]. 280 
Last, the solution or suspension administered should have room temperature not to induce unnecessary 281 
stress to the animals.  282 
Oral administration of tablets or capsules is an alternative to oral gavage of liquids. As seen from Table 1 283 
and 2, tablets are administered by placement in the deep throat thus, activating the swallowing reflex of 284 
the animal. The capsules are dosed by utilizing a commercially available steel device for the dosing of the 285 
capsules to the stomach. For both tablets and capsules, the size hereof must be scaled to the animal to 286 
which it is administered [201]. Although, certain sizes are recommended, it has been shown that enteric-287 
coated capsules of a commercially available size scaled to rats (7.18 mm in length) do not reach the 288 
intestine after dosing to rats, but remains in the stomach, where they dissolve [205]. Interestingly, if 289 
shortening the capsules to a length of 3.5 mm, they may be emptied from the stomach to the intestine. The 290 
study also concluded on a faster gastric emptying and transit of the capsule to the intestine in fed state 291 
animals as compared to animals in the fasted state [205]. The potential drawback of using the shortened 292 
capsules is a very limited loading capacity and also difficulty in handling the small capsules. Moreover, one 293 
should aim for achieving a homogeneous coating of the capsules (or tablets), and avoid scratches in the 294 
coating during handling and dosing, as this is likely to significantly impact the in vivo faith of the dosage 295 
form thus, induce sample variation. Also, powders can be administered via oral gavage, using a positive 296 
displacement pipetting device [206]. 297 
Compared to oral gavage, intragastric and intraintestinal administrations are more invasive procedures 298 
requiring surgical skills of the research personnel and also utilization of anesthesia. Nevertheless, when 299 
considering the previously mentioned correlation (section 6.1) between bioavailability in rat and human 300 
being r2=0.29 and r2=0.8 (after intragastric administration) [176], these methods are highly relevant to 301 
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consider. Many variations of this procedure exist, including whether the DDS is administered by injection to 302 
the absorption site or dosed via an inserted cannula. In addition, the DDS may also be administered to 303 
different regions of the intestine and then it is important to consider if the DDS is administered under 304 
anesthesia (which is always the case for injections to the GI tract) or after a recovery period in conscious 305 
cannulated animals. Regarding the effect of anesthesia, the reader is referred to the discussion in section 306 
6.2.  307 
For injections or in situ studies, the material of the potential cannulas should be carefully considered [207]. 308 
A recent review provides, a very useful overview of pros and cons of the available materials [207]. In brief, 309 
the most important aspects to consider are the biocompatibility, the cannula inner wall diameter (in 310 
relation to the DDS administered) and risk of bacterial adherence. Moreover, flexibility of the material and 311 
chemical and temperature resistance are also important as a soft material of the cannula is less of a burden 312 
for the animal compared to a less flexible material [207]. The parameters are more or less essential 313 
depending on the length of the study and if the animals are to recover from surgery for a longer time 314 
before the experiment can start, or are anesthetized during the whole study. When working with conscious 315 
models, it is important to perform the surgical procedure under as clean conditions as possible, and 316 
therefore, autoclaving the cannula can be important [207]. 317 
Summing up, there are pros and cons for both oral gavage, intragastric or intraintestinal administration. 318 
Oral gavage is less invasive and requires moderate training of research personnel, whereas intragastric and 319 
intraintestinal administrations are invasive and requires intensive surgical training. Also, taking the one-320 
week recovery period into account, the throughput is lower for intragastric and intraintestinal 321 
administrations compared to oral gavage. A significant disadvantage of oral gavage is, however, the very 322 
limited correlation to man, whereas a good correlation exists for intragastric administration. This is an 323 
important aspect to consider, due to the very limited oral bioavailability of biopharmaceuticals.  324 
 325 
6.4. Blood sampling methods 326 
When evaluating DDS in animal models, the most common readout is a pharmacological effect or 327 
pharmacokinetic profiling, either by quantification of blood glucose after dosing biopharmaceuticals such 328 
as insulin and GLP-1 or by compound-specific assays such as enzyme-linked immunosorbent assays (ELISA). 329 
Thus, collection of blood samples is essential, and as for all aspects of animal studies, this also involves 330 
careful consideration of the advantages and drawbacks of the methods available in order to induce least 331 
possible stress to the animals. In Figure 5, the used methods for blood sampling can be observed (compiled 332 
from studies reported in Table 1 and 2). 333 
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Figure 5: Overview of sampling methods used to evaluate oral bioavailability of insulin (A) and other 334 
biopharmaceuticals (B) following in vivo, in situ or ex vivo studies. The graphs are based on the reviewed 335 
papers listed in Table 1 and 2.  336 
 337 
From Figure 5, it is clear that blood sampling from the tail vein is by far the most commonly used method in 338 
mice and rats. However, several methods exist to collect blood from the tail vein [201,208], and it can be 339 
performed on the animals either in conscious or anaesthetized state. One approach is to use a restrainer, 340 
where the animal enters with their head first and the tail is secured in place by a plug or stopper [207]. For 341 
minimizing applying stress to the animals, a red or dark tube is favorable [207], together with frequent 342 
washing to avoid cross infection and pheromonal deposition [208]. Once having fixated the rat, the blood 343 
can be collected either by vein puncturing using a lancet or needle, or by insertion of a temporary surgical 344 
cannula for repeated sample collection. Prior to the sampling, the tail can either be dipped into lukewarm 345 
water or placed under a heating lamp to ease access to the tail vein [208], and the blood is typically 346 
collected using a capillary tube. An alternative is milking of the tail, where a puncture on the vein is 347 
conducted, and the blood is milked out. Here, extreme care must be taken not to rub the tail too intensely, 348 
as this may result in leucocytosis and burns. Administration of local analgesic cream prior to sample 349 
collection can reduce the stress induced on the animals [208]. Alternative to a restrainer, a towel [207] or 350 
even the hands can be used to wrap the animals, keeping the tail free, but whereas the restrainer only 351 
requires one person, two persons are needed for these procedures. 352 
Collection of blood from the eye is the second most used blood sampling method for assessment of orally 353 
administered biopharmaceuticals (Figure 5). The animals do need to be anaesthetized during blood 354 
sampling, and it is not recommended for repeated blood sampling as there is a potential damage of the 355 
eye, and in addition also much stress is induced to the animal [208].  356 
For repeated blood sampling, insertion of a cannula should be considered in order to reduce the stress of 357 
the animal. According to Figure 5, the jugular vein or alternatively the carotid artery are commonly used in 358 
rats, although these methods require intensive surgical training of the research personnel. The surgery is 359 
conducted under full anesthesia, and blood samples can be collected in either the anaesthetized or 360 
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conscious state. During surgery, the jugular vein or carotid artery is localized, a small incision is made into 361 
the vein or artery and the cannula is carefully inserted and securely fastened. For studies with conscious 362 
animals, the cannula is tunneled under the skin to exit in the neck and a harness is employed [207,208]. The 363 
surgery must be done in a clean environment to avoid infections. The considerations regarding the choice 364 
of cannula are as described for intragastric and intraintestinal administrations in section 6.3. When 365 
collecting blood, the cannula is flushed with sterile saline added anticoagulant between sample collection, 366 
and it is highly important to minimize dilution of the blood by using the lowest possible volume of saline. 367 
Heparin and EDTA are the most commonly used anticoagulants, and it is of course important to consider a 368 
potential interference of the anticoagulant with the biopharmaceutical in the analytical assay.  369 
Blood sampling from the oral cavity or the sublingual tongue vein is also a possibility. This is a fast and easy 370 
method, but there is a significant risk of contamination of these samples when the biopharmaceutical is 371 
dosed using oral gavage. Moreover, this method can only be conducted in conscious state, and requires 372 
restrain of the animals hence, risk of inducing unnecessary stress to the animals.  373 
 374 
6.5. Analytical methods 375 
An overview of the analytical methods used after drug administration is given in Figure 6. When evaluating 376 
insulin, blood glucose is the most common readout (Figure 6A). Besides, providing information of the 377 
pharmacodynamics regarding the effect of the administered biopharmaceutical, it is also a valuable tool to 378 
continuously monitor the animal burden while conducting the experiment, and thereby, preventing 379 
hypoglycemia in the animals. For testing other biopharmaceuticals than insulin, the preferred analytical 380 
method is compound-specific assays such as ELISA and radioimmunoassays providing pharmacokinetic data 381 
(Figure 6B), and these methods are often second choice when evaluating insulin-loaded DDS.  382 
Supplementary to the aforementioned methods, microscopic and spectroscopic techniques can be used. 383 
Here, information regarding deposition and mechanistic behavior of the DDS can be gained. Those methods 384 
are usually conducted after euthanisation, and do therefore only provide information for specific time 385 
points. Consequently, if using these methods, more animals are used to assess the in vivo faith of a DDS 386 
over time. Alternative methods such as single photon emission computed tomography/computerized 387 
tomography (SPECT/CT) can be considered, and here the labeled DDS is administered via the chosen route 388 
of administration, and the in vivo faith of the administered sample is followed over time [209]. A significant 389 
drawback of this approach is, however, that it requires very expensive equipment and radiolabeling of the 390 
test compounds immediately prior to administration. However, the method allows for collection of images 391 
of whole animals, the distribution of the label can be quantified, and the method also allows for 3D imaging 392 
[209]. Fluorescence detection in animals is also possible, but can be difficult and also demands labeling of 393 
the DDS (or biopharmaceutical) with a fluorescence probe [210]. 394 
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Figure 6: 395 
Overview of the analytical methods used to evaluate oral bioavailability of insulin (A) and other 396 
biopharmaceuticals (B) in vivo, in situ or ex vivo. This is based on the reviewed papers listed in Table 1 and 397 
2. 398 
 399 
7. Combining and correlating models 400 
IVIVC (also referred to as in vivo in vitro relationship) is a major area of interest both for academia and 401 
industry, and is included in both the European Medicines Agency (EMA) and the Food & Drug 402 
Administration (FDA) guidelines [12]. A recent review by Sjögren et al. [12], thoroughly addresses IVIVC and 403 
its applications in relation to characterization of DDS, and it will be presented here in brief. IVIVC is 404 
mathematically derived as the predicted correlation between in vitro dissolution and/or cell models and in 405 
vivo exposure, yet the term is often used to link in vitro behavior to clinical prediction or results [12]. 406 
Knowledge about IVIVC is highly important, as it is used for understanding how, and to which extent, 407 
changes in the DDS or manufacturing process influence clinical safety and efficacy. Thus, it is a very 408 
important tool from an industrial and regulatory perspective, as it is also used as a quality control 409 
parameter after product launch [12].  410 
 411 
8. Conclusions 412 
Despite the increasing interest in oral delivery of biopharmaceuticals, crucial gaps still exist in relation to 413 
knowledge and development of animal models and suitable experimental settings for assessment of 414 
biopharmaceuticals dosed by the oral route. As of today, most knowledge of the assessment of oral drugs 415 
and the correlation between animal and human studies is based on small molecules. When evaluating 416 
orally administered biopharmaceuticals, it is even more crucial to keep in mind that the animal models will 417 
merely be models, and as the bioavailability is expected to be very low thorough considerations are 418 
essential for all the experimental details, in order to minimize experimental variability and risk of false 419 
readouts. This review provides an overview of some of the most important factors influencing the 420 
assessment of oral biopharmaceuticals. The review describes the available models and experimental setting 421 
used for testing biopharmaceuticals and serves to provide an overview of which animals and methods are 422 
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commonly used when testing oral delivery of biopharmaceuticals. Furthermore, it addresses considerations 423 
related to use of anesthesia and the effect this can have on the readout of the studies. Likewise, 424 
considerations related to blood sampling procedures and analytical methods are discussed in this review.  425 
It is impossible to generalize on which models and methods to utilize in specific studies, but this review 426 
presents the advantages and disadvantages of the various methods used so far, hence easing the test 427 
designs regarding animal models and methods for the evaluation of biopharmaceuticals to be administered 428 
by the oral route.   429 
 430 
Conflicts of interest 431 
None 432 
 433 
Acknowledgements 434 
The authors acknowledge Dr. Tri-Hung Nguyen and Prof. Christopher J. Porter (Monash University, 435 
Melbourne, Australia) for valuable scientific discussions and introduction to in vivo studies. Dr. Peter 436 
Thygesen (Novo Nordisk, Måløv), Dr. Ulrich Werner, Mario Funke, Dominik Hartmann and Dr. Melissa 437 
Besenius (Sanofi, Frankfurt) are also thanked for valuable discussions. Nanna Bild, Technical University of 438 
Denmark is acknowledged for the drawing of the schematics. Furthermore, Mechthild Schmitt and Maxim 439 
Antopolski (Faculty of Pharmacy, University of Helsinki) are thanked for providing the SPECT-CT images 440 
shown in the graphical abstract. Last, Mathilde Caldera (University of Copenhagen) is thanked for always 441 
being helpful and providing valuable inputs for setting up in vivo studies.  442 
Funding 443 
The research leading to these results has received support from the Innovative Medicines Initiative Joint 444 
Undertaking under grant agreement nº 115363 resources which are composed of financial contribution 445 
from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind 446 
contribution (SHH). The Danish Research Council for Technology and Production (FTP) (project DFF-4004-447 
00120B) is acknowledged for financial support (LHN), and in addition, the Danmarks Grundforskningsfonds 448 
(project DNRF122) and Villum Fondens Center for Intelligent Drug Delivery and Sensing Using 449 
Microcontainers and Nanomechanics (IDUN) is acknowledged. 450 
 451 
References 452 
[1] J.H. Hamman, G.M. Enslin, A.F. Kotzé, Oral delivery of peptide drugs, BioDrugs. 19 (2005) 165–177. 453 
doi:10.2165/00063030-200519030-00003. 454 
[2] Global peptide therapeutics pipeline insight 2015, ID 3096565. (2015). 455 
http://www.researchandmarkets.com/publication/msloabz/global_peptide_therapeutics_pipeline_i456 
nsighGlobal (accessed November 1, 2016). 457 
[3] B.F. Choonara, Y.E. Choonara, P. Kumar, D. Bijukumar, L.C. du Toit, V. Pillay, A review of advanced 458 
oral drug delivery technologies facilitating the protection and absorption of protein and peptide 459 
molecules, Biotechnol. Adv. 32 (2014) 1269–82. doi:10.1016/j.biotechadv.2014.07.006. 460 
[4] K. Ganguly, K. Chaturvedi, U.A. More, M.N. Nadagouda, T.M. Aminabhavi, Polysaccharide-based 461 
micro/nanohydrogels for delivering macromolecular therapeutics, J. Control. Release. 193 (2014) 462 
162–173. doi:10.1016/j.jconrel.2014.05.014. 463 
[5] A.L. Smart, S. Gaisford, A.W. Basit, Oral peptide and protein delivery: intestinal obstacles and 464 
commercial prospects, Expert Opin. Drug Deliv. 11 (2014) 1323–35. 465 
doi:10.1517/17425247.2014.917077. 466 
 26 
[6] J. Renukuntla, A.D. Vadlapudi, A. Patel, S.H.S. Boddu, A.K. Mitra, Approaches for enhancing oral 467 
bioavailability of peptides and proteins, Int. J. Pharm. 447 (2013) 75–93. 468 
doi:10.1016/j.ijpharm.2013.02.030. 469 
[7] P.L. Lam, R. Gambari, Advanced progress of microencapsulation technologies: In vivo and in vitro 470 
models for studying oral and transdermal drug deliveries, J. Control. Release. 178 (2014) 25–45. 471 
doi:10.1016/j.jconrel.2013.12.028. 472 
[8] S.R. Hwang, Y. Byun, Advances in oral macromolecular drug delivery, Expert Opin. Drug Deliv. 11 473 
(2014) 1–13. doi:10.1517/17425247.2014.945420. 474 
[9] P. Colombo, F. Sonvico, G. Colombo, R. Bettini, Novel platforms for oral drug delivery, Pharm. Res. 475 
26 (2009) 601–611. doi:10.1007/s11095-008-9803-0. 476 
[10] E. Moroz, S. Matoori, J.C. Leroux, Oral delivery of macromolecular drugs: Where we are after almost 477 
100years of attempts, Adv. Drug Deliv. Rev. 101 (2016) 108–121. doi:10.1016/j.addr.2016.01.010. 478 
[11] J. Iqbal, G. Shahnaz, G. Perera, F. Hintzen, F. Sarti, A. Bernkop-Schnürch, Thiolated chitosan: 479 
development and in vivo evaluation of an oral delivery system for leuprolide, Eur. J. Pharm. 480 
Biopharm. 80 (2012) 95–102. doi:10.1016/j.ejpb.2011.09.010. 481 
[12] E. Sjögren, B. Abrahamsson, P. Augustijns, D. Becker, M.B. Bolger, M. Brewster, J. Brouwers, T. 482 
Flanagan, M. Harwood, C. Heinen, R. Holm, H.P. Juretschke, M. Kubbinga, A. Lindahl, V. Lukacova, U. 483 
Münster, S. Neuhoff, M.A. Nguyen, A. Van Peer, C. Reppas, A.R. Hodjegan, C. Tannergren, W. 484 
Weitschies, C. Wilson, P. Zane, H. Lennernäs, P. Langguth, In vivo methods for drug absorption - 485 
Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and 486 
applications for formulation/API/excipient characterization including food effects, Eur. J. Pharm. Sci. 487 
57 (2014) 99–151. doi:10.1016/j.ejps.2014.02.010. 488 
[13] J.M. Gamboa, K.W. Leong, In vitro and in vivo models for the study of oral delivery of nanoparticles, 489 
Adv. Drug Deliv. Rev. 65 (2013) 800–810. doi:10.1016/j.addr.2013.01.003. 490 
[14] C.A.S. Bergström, W.N. Charman, C.J.H. Porter, Computational prediction of formulation strategies 491 
for beyond-rule-of-5 compounds, Adv. Drug Deliv. Rev. 101 (2016) 6–21. 492 
doi:10.1016/j.addr.2016.02.005. 493 
[15] G. Traverso, C.M. Schoellhammer, A. Schroeder, R. Maa, G.Y. Lauwers, B.E. Polat, D.G. Anderson, D. 494 
Blankschtein, R. Langer, Microneedles for drug delivery via the gastrointestinal tract, J. Pharm. Sci. 495 
104 (2015) 362–367. doi:10.1002/jps.24182. 496 
[16] V.F. Patel, F. Liu, M.B. Brown, Advances in oral transmucosal drug delivery, J. Control. Release. 153 497 
(2011) 106–116. doi:10.1016/j.jconrel.2011.01.027. 498 
[17] M. Morishita, N.A. Peppas, Is the oral route possible for peptide and protein drug delivery?, Drug 499 
Discov. Today. 11 (2006) 905–10. doi:10.1016/j.drudis.2006.08.005. 500 
[18] F. Antunes, F. Andrade, D. Ferreira, H.M. Nielsen, B. Sarmento, Models to predict intestinal 501 
absorption of therapeutic peptides and proteins, Curr. Drug Metab. 14 (2013) 4–20. 502 
doi:10.2174/138920013804545160. 503 
[19] N. Fotaki, Pros and cons of methods used for the prediction of oral drug absorption, Expert Rev. Clin. 504 
Pharmacol. 2 (2009) 195–208. doi:10.1586/17512433.2.2.195. 505 
[20] G. Camenisch, J. Alsenz, H. Van De Waterbeemd, G. Folkers, Estimation of permeability by passive 506 
diffusion through Caco-2 cell monolayers using the drugs’ lipophilicity and molecular weight, Eur. J. 507 
Pharm. Sci. 6 (1998) 313–319. doi:10.1016/S0928-0987(97)10019-7. 508 
[21] A. Bayat, F.A. Dorkoosh, A.R. Dehpour, L. Moezi, B. Larijani, H.E. Junginger, M. Rafiee-Tehrani, 509 
Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: Ex vivo 510 
and in vivo studies, Int. J. Pharm. 356 (2008) 259–266. doi:10.1016/j.ijpharm.2007.12.037. 511 
[22] E. Déat-Lainé, V. Hoffart, G. Garrait, J.F. Jarrige, J.M. Cardot, M. Subirade, E. Beyssac, Efficacy of 512 
mucoadhesive hydrogel microparticles of whey protein and alginate for oral insulin delivery, Pharm. 513 
Res. 30 (2013) 721–734. doi:10.1007/s11095-012-0913-3. 514 
[23] L. Hovgaard, H. Jacobs, D.E. Wilson, S.W. Kim, Stabilization of insulin by alkylmaltosides. B. Oral 515 
absorption in vivo in rats, Int. J. Pharm. 132 (1996) 115–121. doi:10.1016/0378-5173(95)04414-0. 516 
 27 
[24] K. Sonaje, Y.-H. Lin, J.-H. Juang, S.-P. Wey, C.-T. Chen, H.-W. Sung, In vivo evaluation of safety and 517 
efficacy of self-assembled nanoparticles for oral insulin delivery, Biomaterials. 30 (2009) 2329–39. 518 
doi:10.1016/j.biomaterials.2008.12.066. 519 
[25] M. Trotta, M.E. Carlotti, M. Gallarate, G.P. Zara, E. Muntoni, L. Battaglia, Insulin-loaded SLN 520 
prepared with the emulsion dilution technique: In vivo tracking of nanoparticles after oral 521 
administration to rats, J. Dispers. Sci. Technol. 32 (2011) 1041–1045. 522 
doi:10.1080/01932691.2010.488497. 523 
[26] N. Li, X.-R. Li, Y.-X. Zhou, W.-J. Li, Y. Zhao, S.-J. Ma, J.-W. Li, Y.-J. Gao, Y. Liu, X.-L. Wang, D.-D. Yin, The 524 
use of polyion complex micelles to enhance the oral delivery of salmon calcitonin and transport 525 
mechanism across the intestinal epithelial barrier, Biomaterials. 33 (2012) 8881–92. 526 
doi:10.1016/j.biomaterials.2012.08.047. 527 
[27] M. Niu, Y. Tan, P. Guan, L. Hovgaard, Y. Lu, J. Qi, R. Lian, X. Li, W. Wu, Enhanced oral absorption of 528 
insulin-loaded liposomes containing bile salts: A mechanistic study, Int. J. Pharm. 460 (2014) 119–529 
130. doi:10.1016/j.ijpharm.2013.11.028. 530 
[28] Y. Zhang, X. Lin, X. Du, S. Geng, H. Li, H. Sun, X. Tang, W. Xiao, pH-sensitive thiolated nanoparticles 531 
facilitate the oral delivery of insulin in vitro and in vivo, J. Nanoparticle Res. 17 (2015) 1–11. 532 
doi:10.1007/s11051-014-2847-7. 533 
[29] A.M.M. Sadeghi, M.R. Avadi, S. Ejtemaimehr, S. Abashzadeh, A. Partoazar, F. Dorkoosh, M. Faghihi, 534 
M. Rafiee-Tehrani, H.E. Junginger, Development of a gas empowered drug delivery system for 535 
peptide delivery in the small intestine, J. Control. Release. 134 (2009) 11–17. 536 
doi:10.1016/j.jconrel.2008.10.012. 537 
[30] L. Yin, J. Ding, L. Fei, M. He, F. Cui, C. Tang, C. Yin, Beneficial properties for insulin absorption using 538 
superporous hydrogel containing interpenetrating polymer network as oral delivery vehicles, Int. J. 539 
Pharm. 350 (2008) 220–229. doi:10.1016/j.ijpharm.2007.08.051. 540 
[31] X. Li, S. Guo, C. Zhu, Q. Zhu, Y. Gan, J. Rantanen, U.L. Rahbek, L. Hovgaard, M. Yang, Intestinal 541 
mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles, 542 
Biomaterials. 34 (2013) 9678–9687. doi:10.1016/j.biomaterials.2013.08.048. 543 
[32] G. Sandri, M.C. Bonferoni, S. Rossi, F. Ferrari, C. Boselli, C. Caramella, Insulin-loaded nanoparticles 544 
based on N-trimethyl chitosan: in vitro (Caco-2 model) and ex vivo (excised rat jejunum, duodenum, 545 
and ileum) evaluation of penetration enhancement properties, AAPS PharmSciTech. 11 (2010) 362–546 
71. doi:10.1208/s12249-010-9390-3. 547 
[33] A. Verma, S. Sharma, P.K. Gupta, A. Singh, B.V. Teja, P. Dwivedi, G.K. Gupta, R. Trivedi, P.R. Mishra, 548 
Vitamin B12 functionalized layer by layer calcium phosphate nanoparticles: A mucoadhesive and pH 549 
responsive carrier for improved oral delivery of insulin, Acta Biomater. 31 (2016) 288–300. 550 
doi:10.1016/j.actbio.2015.12.017. 551 
[34] A. Fasano, S. Uzzau, Modulation of intestinal tight junctions by zonula occludens toxin permits 552 
enteral administration of insulin and other macromolecules in an animal model, J. Clin. Invest. 99 553 
(1997) 1158–1164. doi:10.1172/JCI119271. 554 
[35] H. He, J. Sheng, A.E. David, Y.M. Kwon, J. Zhang, Y. Huang, J. Wang, V.C. Yang, The use of low 555 
molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption, 556 
Biomaterials. 34 (2013) 7733–7743. doi:10.1016/j.biomaterials.2013.06.047. 557 
[36] C. Damgé, P. Maincent, N. Ubrich, Oral delivery of insulin associated to polymeric nanoparticles in 558 
diabetic rats, J. Control. Release. 117 (2007) 163–170. doi:10.1016/j.jconrel.2006.10.023. 559 
[37] K. Iwanaga, S. Ono, K. Narioka, M. Kakemi, K. Morimoto, S. Yamashita, Y. Namba, O. Naoto, 560 
Application of surface-coated liposomes for oral delivery of peptide: Effects of coating the 561 
liposome’s surface on the GI transit of insulin, J. Pharm. Sci. 88 (1999) 248–252. 562 
doi:10.1021/js980235x. 563 
[38] J. Shimoda, H. Onishi, Y. Machida, Bioadhesive characteristics of chitosan microspheres to the 564 
mucosa of rat small intestine, Drug Dev. Ind. Pharm. 27 (2001) 567–76. doi:10.1081/DDC-565 
100105182. 566 
 28 
[39] A. Tuesca, K. Nakamura, M. Morishita, J. Joseph, N. Peppas, A. Lowman, Complexation hydrogels for 567 
oral insulin delivery: Effects of polymer dosing on in vivo efficacy, J. Pharm. Sci. 97 (2008) 2607–568 
2618. doi:10.1002/jps.21184. 569 
[40] E.-S. Khafagy, R. Iwamae, N. Kamei, M. Takeda-Morishita, Region-dependent role of cell-penetrating 570 
peptides in insulin absorption across the rat small intestinal membrane, AAPS J. 17 (2015) 1427–571 
1437. doi:10.1208/s12248-015-9804-y. 572 
[41] N. Kamei, M. Morishita, Y. Kanayama, K. Hasegawa, M. Nishimura, E. Hayashinaka, Y. Wada, Y. 573 
Watanabe, K. Takayama, Molecular imaging analysis of intestinal insulin absorption boosted by cell-574 
penetrating peptides by using positron emission tomography, J. Control. Release. 146 (2010) 16–22. 575 
doi:10.1016/j.jconrel.2010.05.004. 576 
[42] N. Ahmad, M.C.I. Mohd Amin, I. Ismail, F. Buang, Enhancement of oral insulin bioavailability: in vitro 577 
and in vivo assessment of nanoporous stimuli-responsive hydrogel microparticles, Expert Opin. Drug 578 
Deliv. 13 (2016) 621–632. doi:10.1517/17425247.2016.1160889. 579 
[43] Y. Jin, Y. Song, X. Zhu, D. Zhou, C. Chen, Z. Zhang, Y. Huang, Goblet cell-targeting nanoparticles for 580 
oral insulin delivery and the influence of mucus on insulin transport, Biomaterials. 33 (2012) 1573–581 
1582. doi:10.1016/j.biomaterials.2011.10.075. 582 
[44] A. Kadir, M.T.M. Mokhtar, T.W. Wong, Nanoparticulate assembly of mannuronic acid- and guluronic 583 
acid-rich alginate: Oral insulin carrier and glucose binder, J. Pharm. Sci. 102 (2013) 4353–4363. 584 
doi:10.1002/jps.23742. 585 
[45] N. Reix, A. Parat, E. Seyfritz, R. Van Der Werf, V. Epure, N. Ebel, L. Danicher, E. Marchioni, N. 586 
Jeandidier, M. Pinget, Y. Frère, S. Sigrist, In vitro uptake evaluation in Caco-2 cells and in vivo results 587 
in diabetic rats of insulin-loaded PLGA nanoparticles, Int. J. Pharm. 437 (2012) 213–220. 588 
doi:10.1016/j.ijpharm.2012.08.024. 589 
[46] Z.H. Zhang, Y.L. Zhang, J.P. Zhou, H.X. Lv, Solid lipid nanoparticles modified with stearic acid-590 
octaarginine for oral administration of insulin, Int. J. Nanomedicine. 7 (2012) 3333–3339. 591 
doi:10.2147/IJN.S31711. 592 
[47] M. Diop, N. Auberval, A. Viciglio, A. Langlois, W. Bietiger, C. Mura, C. Peronet, A. Bekel, D. Julien 593 
David, M. Zhao, M. Pinget, N. Jeandidier, C. Vauthier, E. Marchioni, Y. Frere, S. Sigrist, Design, 594 
characterisation, and bioefficiency of insulin-chitosan nanoparticles after stabilisation by freeze-595 
drying or cross-linking, Int. J. Pharm. 491 (2015) 402–408. doi:10.1016/j.ijpharm.2015.05.065. 596 
[48] F. Cui, F. Qian, Z. Zhao, L. Yin, C. Tang, C. Yin, Preparation, characterization, and oral delivery of 597 
insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles, 598 
Biomacromolecules. 10 (2009) 1253–1258. doi:10.1021/bm900035u. 599 
[49] V. Gupta, B.H. Hwang, N. Doshi, A. Banerjee, A.C. Anselmo, S. Mitragotri, Delivery of exenatide and 600 
insulin using mucoadhesive intestinal devices, Ann. Biomed. Eng. 44 (2016) 1–15. 601 
doi:10.1007/s10439-016-1558-x. 602 
[50] F. Cui, F. Qian, Z. Zhao, L. Yin, C. Tang, C. Yin, Preparation, characterization, and oral delivery of 603 
insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles, 604 
Biomacromolecules. 10 (2009) 1253–1258. doi:10.1021/bm900035u. 605 
[51] S. Sun, N. Liang, Y. Kawashima, D. Xia, F. Cui, Hydrophobic ion pairing of an insulin-sodium 606 
deoxycholate complex for oral delivery of insulin, Int. J. Nanomedicine. 6 (2011) 3049–3056. 607 
doi:10.2147/IJN.S26450. 608 
[52] B. Sarmento, S. Martins, Oral insulin delivery by means of solid lipid nanoparticles, 2 (2007) 743–609 
749. doi:10.1177/193229681300700228. 610 
[53] B. Sarmento, A. Ribeiro, F. Veiga, P. Sampaio, R. Neufeld, D. Ferreira, Alginate/chitosan 611 
nanoparticles are effective for oral insulin delivery, Pharm. Res. 24 (2007) 2198–2206. 612 
doi:10.1007/s11095-007-9367-4. 613 
[54] B. Sarmento, A. Ribeiro, F. Veiga, D. Ferreira, R. Neufeld, Oral bioavailability of insulin contained in 614 
polysaccharide nanoparticles, Biomacromolecules. 8 (2007) 3054–3060. doi:10.1021/bm0703923. 615 
[55] P. Fonte, T. Nogueira, C. Gehm, D. Ferreira, B. Sarmento, Chitosan-coated solid lipid nanoparticles 616 
 29 
enhance the oral absorption of insulin, Drug Deliv. Transl. Res. 1 (2011) 299–308. 617 
doi:10.1007/s13346-011-0023-5. 618 
[56] A. Graf, T. Rades, S.M. Hook, Oral insulin delivery using nanoparticles based on microemulsions with 619 
different structure-types: Optimisation and in vivo evaluation, Eur. J. Pharm. Sci. 37 (2009) 53–61. 620 
doi:10.1016/j.ejps.2008.12.017. 621 
[57] P. Hurkat, A. Jain, A. Jain, S. Shilpi, A. Gulbake, S.K. Jain, Concanavalin A conjugated biodegradable 622 
nanoparticles for oral insulin delivery, J. Nanoparticle Res. 14 (2012) 1219. doi:10.1007/s11051-012-623 
1219-4. 624 
[58] P. Mukhopadhyay, P.P. Kundu, Chitosan-graft-PAMAM–alginate core–shell nanoparticles: a safe and 625 
promising oral insulin carrier in an animal model, RSC Adv. 5 (2015) 93995–94007. 626 
doi:10.1039/C5RA17729D. 627 
[59] L. Yin, J. Ding, C. He, L. Cui, C. Tang, C. Yin, Drug permeability and mucoadhesion properties of 628 
thiolated trimethyl chitosan nanoparticles in oral insulin delivery, Biomaterials. 30 (2009) 5691–629 
5700. doi:10.1016/j.biomaterials.2009.06.055. 630 
[60] K. Whitehead, Z. Shen, S. Mitragotri, Oral delivery of macromolecules using intestinal patches: 631 
Applications for insulin delivery, J. Control. Release. 98 (2004) 37–45. 632 
doi:10.1016/j.jconrel.2004.04.013. 633 
[61] E.J.B. Nielsen, S. Yoshida, N. Kamei, R. Iwamae, E.S. Khafagy, J. Olsen, U.L. Rahbek, B.L. Pedersen, K. 634 
Takayama, M. Takeda-Morishita, In vivo proof of concept of oral insulin delivery based on a co-635 
administration strategy with the cell-penetrating peptide penetratin, J. Control. Release. 189 (2014) 636 
19–24. doi:10.1016/j.jconrel.2014.06.022. 637 
[62] C.J. Kirby, Oil-based formulations for oral delivery of therapeutic peptides, J. Liposome Res. 10 638 
(2000) 391–407. doi:10.3109/08982100009031106. 639 
[63] P. Calceti, S. Salmaso, G. Walker, A. Bernkop-Schnürch, Development and in vivo evaluation of an 640 
oral insulin-PEG delivery system, Eur. J. Pharm. Sci. 22 (2004) 315–323. 641 
doi:10.1016/j.ejps.2004.03.015. 642 
[64] M.K. Marschütz, P. Caliceti, A. Bernkop-Schnürch, Design and in vivo evaluation of an oral delivery 643 
system for insulin, Pharm. Res. 17 (2000) 1468–1474. doi:10.1023/A:1007696723125. 644 
[65] M. Werle, B. Loretz, D. Entstrasser, F. Föger, Design and evaluation of a chitosan-aprotinin conjugate 645 
for the peroral delivery of therapeutic peptides and proteins susceptible to enzymatic degradation, 646 
J. Drug Target. 15 (2007) 327–333. doi:10.1080/10611860701349141. 647 
[66] B. Deutel, M. Greindl, M. Thaurer, A. Bernkop-Schnürch, Novel insulin thiomer nanoparticles: In vivo 648 
evaluation of an oral drug delivery system, Biomacromolecules. 9 (2008) 278–285. 649 
doi:10.1021/bm700916h. 650 
[67] G. Millotti, F. Laffleur, G. Perera, C. Vigl, K. Pickl, F. Sinner, A. Bernkop-Schnürch, In vivo evaluation 651 
of thiolated chitosan tablets for oral insulin delivery, J. Pharm. Sci. 103 (2014) 3165–3170. 652 
doi:10.1002/jps.24102. 653 
[68] A.H. Krauland, D. Guggi, A. Bernkop-Schnürch, Oral insulin delivery: The potential of thiolated 654 
chitosan-insulin tablets on non-diabetic rats, J. Control. Release. 95 (2004) 547–555. 655 
doi:10.1016/j.jconrel.2003.12.017. 656 
[69] V. Grabovac, F. Föger, A. Bernkop-Schnürch, Design and in vivo evaluation of a patch system based 657 
on thiolated polymers, Int. J. Pharma. 348 (2008) 169–174. doi:10.1016/j.ijpharm.2007.06.052. 658 
[70] A. Maroni, M. Dorly, D. Curto, S. Salmaso, L. Zema, A. Melocchi, P. Caliceti, A. Gazzaniga, In vitro and 659 
in vivo evaluation of an oral multiple-unit formulation for colonic delivery of insulin, Eur. J. Pharm. 660 
Biopharm. 108 (2016) 76–82. doi:10.1016/j.ejpb.2016.08.002. 661 
[71] M.A. Momoh, F.C. Kenechukwu, P.O. Nnamani, J.C. Umetiti, Influence of magnesium stearate on the 662 
physicochemical and pharmacodynamic characteristics of insulin-loaded Eudragit entrapped 663 
mucoadhesive microspheres, Drug Deliv. 7544 (2014) 1–12. doi:10.3109/10717544.2014.898108. 664 
[72] Z.I. Al-Kurdi, B.Z. Chowdhry, S.A. Leharne, N.A. Qinna, M.M.H. Al Omari, A.A. Badwan, Influence of 665 
glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery 666 
 30 
system, Drug Des. Devel. Ther. 9 (2015) 6167–6176. doi:10.2147/DDDT.S91974. 667 
[73] F. Yu, Y. Li, C.S. Liu, Q. Chen, G.H. Wang, W. Guo, X.E. Wu, D.H. Li, W.D. Wu, X.D. Chen, Enteric-668 
coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles 669 
for oral delivery of insulin, Int. J. Pharm. 484 (2015) 181–191. doi:10.1016/j.ijpharm.2015.02.055. 670 
[74] S. Abbad, Z. Zhang, A.Y. Waddad, W.L.L. Munyendo, H. Lv, J. Zhou, Chitosan-modified cationic amino 671 
acid nanoparticles as a novel oral delivery system for insulin, J. Biomed. Nanotechnol. 11 (2015) 672 
486–499. doi:10.1166/jbn.2015.1924. 673 
[75] K.H. Leong, L.Y. Chung, M.I. Noordin, Y. Onuki, M. Morishita, K. Takayama, Lectin-functionalized 674 
carboxymethylated kappa-carrageenan microparticles for oral insulin delivery, Carbohydr. Polym. 86 675 
(2011) 555–565. doi:10.1016/j.carbpol.2011.04.070. 676 
[76] L. Zhang, Z. Zhang, N. Li, N. Wang, Y. Wang, S. Tang, L. Xu, Y. Ren, Synthesis and evaluation of a novel 677 
β-cyclodextrin derivative for oral insulin delivery and absorption, Int. J. Biol. Macromol. 61 (2013) 678 
494–500. doi:10.1016/j.ijbiomac.2013.08.034. 679 
[77] Z. Wu, L. Ling, L. Zhou, X. Guo, W. Jiang, Y. Qian, K. Luo, L. Zhang, Novel preparation of PLGA/HP55 680 
nanoparticles for oral insulin delivery, Nanoscale Res. Lett. 7 (2012) 299. doi:10.1186/1556-276X-7-681 
299. 682 
[78] B. D’Souza, T. Bhowmik, M.N. Uddin, C. Oettinger, M. D’Souza, Development of b-cyclodextrin-683 
based sustained release microparticles for oral insulin delivery, Drug Dev. Ind. Pharm. Ind Pharm. 684 
9045 (2014) 1–6. doi:10.3109/03639045.2014.947507. 685 
[79] M. Licciardi, G. Pitarresi, G. Cavallaro, G. Giammona, Nanoaggregates based on new poly-686 
hydroxyethyl-aspartamide copolymers for oral insulin absorption, Mol. Pharm. 10 (2013) 1644–687 
1654. doi:10.1021/mp300226d. 688 
[80] L. Yin, J. Ding, J. Zhang, C. He, C. Tang, C. Yin, Polymer integrity related absorption mechanism of 689 
superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin, 690 
Biomaterials. 31 (2010) 3347–3356. doi:10.1016/j.biomaterials.2010.01.045. 691 
[81] Y. Zhang, X. Wu, L. Meng, Y. Zhang, R. Ai, N. Qi, H. He, H. Xu, X. Tang, Thiolated Eudragit 692 
nanoparticles for oral insulin delivery: Preparation, characterization and in vivo evaluation, Int. J. 693 
Pharm. 436 (2012) 341–350. doi:10.1016/j.ijpharm.2012.06.054. 694 
[82] V. Uskokovi, Shape effect in the design of nanowire-coated microparticles as transepithelial drug 695 
delivery devices, ACS Nano. 6 (2012) 7832–7841. doi:10.1021/nn3019865. 696 
[83] S. Park, Y. Nho, Y. Lim, H. Kim, Preparation of pH-sensitive poly (vinyl alcohol-g-methacrylic acid) and 697 
poly (vinyl alcohol-g-acrylic acid) hydrogels by gamma ray irradiation and their insulin release 698 
behavior, J. Appl. Polym. Sci. 91 (2004) 636–643. 699 
[84] Y. Dekel, Y. Glucksam, R. Margalit, Novel fibrillar insulin formulations for oral administration: 700 
Formulation and in vivo studies in diabetic mice, J. Control. Release. 143 (2010) 128–135. 701 
doi:10.1016/j.jconrel.2009.12.018. 702 
[85] X.Y. Xiong, Q.H. Li, Y.P. Li, L. Guo, Z.L. Li, Y.C. Gong, Pluronic P85/poly(lactic acid) vesicles as novel 703 
carrier for oral insulin delivery, Colloids Surfaces B Biointerfaces. 111 (2013) 282–288. 704 
doi:10.1016/j.colsurfb.2013.06.019. 705 
[86] P. Mukhopadhyay, K. Sarkar, M. Chakraborty, S. Bhattacharya, R. Mishra, P.P. Kundu, Oral insulin 706 
delivery by self-assembled chitosan nanoparticles: In vitro and in vivo studies in diabetic animal 707 
model, Mater. Sci. Eng. C. 33 (2013) 376–382. doi:10.1016/j.msec.2012.09.001. 708 
[87] S. Salmaso, S. Bersani, N. Elvassore, A. Bertucco, P. Caliceti, Biopharmaceutical characterisation of 709 
insulin and recombinant human growth hormone loaded lipid submicron particles produced by 710 
supercritical gas micro-atomisation, Int. J. Pharm. 379 (2009) 51–58. 711 
doi:10.1016/j.ijpharm.2009.06.014. 712 
[88] N. Zhang, Q.N. Ping, G.H. Huang, W.F. Xu, Investigation of lectin-modified insulin liposomes as 713 
carriers for oral administration, Int. J. Pharm. 294 (2005) 247–259. 714 
doi:10.1016/j.ijpharm.2005.01.018. 715 
[89] H. Rachmawati, B.M. Haryadi, K. Anggadiredja, V. Suendo, Intraoral film containing insulin-716 
 31 
phospholipid microemulsion: Formulation and in vivo hypoglycemic activity study, AAPS 717 
PharmSciTech. 16 (2015) 692–703. doi:10.1208/s12249-014-0258-9. 718 
[90] A.K. Agrawal, H. Harde, K. Thanki, S. Jain, Improved stability and antidiabetic potential of insulin 719 
containing folic acid functionalized polymer stabilized multilayered liposomes following oral 720 
administration, Biomacromolecules. 15 (2014) 350–360. doi:10.1021/bm401580k. 721 
[91] R. Sharma, U. Gupta, N.K. Garg, R.K. Tyagi, N.K. Jain, Surface engineered and ligand anchored 722 
nanobioconjugate: An effective therapeutic approach for oral insulin delivery in experimental 723 
diabetic rats, Colloids Surfaces B Biointerfaces. 127 (2015) 172–181. 724 
doi:10.1016/j.colsurfb.2015.01.035. 725 
[92] K.B. Chalasani, G.J. Russell-Jones, S.K. Yandrapu, P. V. Diwan, S.K. Jain, A novel vitamin B                    726 
12-nanosphere conjugate carrier system for peroral delivery of insulin, J. Control. Release. 117 727 
(2007) 421–429. doi:10.1016/j.jconrel.2006.12.003. 728 
[93] F. Cui, K. Shi, L. Zhang, A. Tao, Y. Kawashima, Biodegradable nanoparticles loaded with insulin-729 
phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation, 730 
J. Control. Release. 114 (2006) 242–250. doi:10.1016/j.jconrel.2006.05.013. 731 
[94] Z. Ma, T.M. Lim, L.Y. Lim, Pharmacological activity of peroral chitosan-insulin nanoparticles in 732 
diabetic rats, Int. J. Pharm. 293 (2005) 271–280. doi:10.1016/j.ijpharm.2004.12.025. 733 
[95] M.A. Radwan, Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres 734 
by sodium cholate after oral and subcutaneous administration in diabetic rats., Drug Dev. Ind. 735 
Pharm. 27 (2001) 981–9. doi:10.1081/DDC-100107680. 736 
[96] S. Sajeesh, K. Bouchemal, V. Marsaud, C. Vauthier, C.P. Sharma, Cyclodextrin complexed insulin 737 
encapsulated hydrogel microparticles: An oral delivery system for insulin, J. Control. Release. 147 738 
(2010) 377–384. doi:10.1016/j.jconrel.2010.08.007. 739 
[97] W. Wei, G.H. Ma, L.Y. Wang, J. Wu, Z.G. Su, Hollow quaternized chitosan microspheres increase the 740 
therapeutic effect of orally administered insulin, Acta Biomater. 6 (2010) 205–209. 741 
doi:10.1016/j.actbio.2009.06.005. 742 
[98] K. Kesavan, G. Nath, J.K. Pandit, Preparation and in vitro antibacterial evaluation of gatifloxacin 743 
mucoadhesive gellan system., J. Fac. Pharmacy, Tehran Univ. Med. Sci. 18 (2010) 237–46. 744 
[99] Y. Pan, Y. Li, H. Zhao, J. Zhen, H. Xu, G. Wei, J. Hao, F. Cui, Bioadhesive polysaccharide in protein 745 
delivery system:chitosan nanoparticles improve the intestinal absorption of insulin in vivo, Int. J. 746 
Pharm. 249 (2002) 139–147. doi:10.1016/S0378-5173(02)00486-6. 747 
[100] P.C. Naha, V. Kanchan, P.K. Manna, A.K. Panda, Improved bioavailability of orally delivered insulin 748 
using Eudragit-L30D coated PLGA microparticles, J. Microencapsul. 25 (2008) 248–256. 749 
doi:10.1080/02652040801903843. 750 
[101] L. Sun, X. Zhang, Z. Wu, C. Zheng, C. Li, Oral glucose- and pH-sensitive nanocarriers for simulating 751 
insulin release in vivo, Polym. Chem. 5 (2014) 1999–2009. doi:10.1039/c3py01416a. 752 
[102] S. Sun, N. Liang, H. Piao, H. Yamamoto, Y. Kawashima, F. Cui, Insulin-S.O (sodium oleate) complex-753 
loaded PLGA nanoparticles: Formulation, characterization and in vivo evaluation, J. Microencapsul. 754 
27 (2010) 471–478. doi:10.3109/02652040903515490. 755 
[103] R. Yang, R. Gao, F. Li, H. He, X. Tang, The influence of lipid characteristics on the formation, in vitro 756 
release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process, 757 
Drug Dev. Ind. Pharm. 37 (2011) 139–48. doi:10.3109/03639045.2010.497151. 758 
[104] L. Zhang, L. Song, C. Zhang, Y. Ren, Improving intestinal insulin absorption efficiency through 759 
coadministration of cell-penetrating peptide and hydroxypropyl-ß-cyclodextrin, Carbohydr. Polym. 760 
87 (2012) 1822–1827. doi:10.1016/j.carbpol.2011.10.002. 761 
[105] P. He, Z. Tang, L. Lin, M. Deng, X. Pang, X. Zhuang, X. Chen, Novel biodegradable and pH-sensitive 762 
poly(ester amide) microspheres for oral insulin delivery, Macromol. Biosci. 12 (2012) 547–556. 763 
doi:10.1002/mabi.201100358. 764 
[106] P. He, H. Liu, Z. Tang, M. Deng, Y. Yang, X. Pang, X. Chen, Poly(ester amide) blend microspheres for 765 
oral insulin delivery, Int. J. Pharm. 455 (2013) 259–266. doi:10.1016/j.ijpharm.2013.07.022. 766 
 32 
[107] C.J. Lim, W.C. Shen, Comparison of monomeric and oligomeric transferrin as potential carrier in oral 767 
delivery of protein drugs, J. Control. Release. 106 (2005) 273–286. 768 
doi:10.1016/j.jconrel.2005.05.001. 769 
[108] Y.H. Lin, F.L. Mi, C.T. Chen, W.C. Chang, S.F. Peng, H.F. Liang, H.W. Sung, Preparation and 770 
characterization of nanoparticles shelled with chitosan for oral insulin delivery, Biomacromolecules. 771 
8 (2007) 146–152. doi:10.1021/bm0607776. 772 
[109] M.R. Rekha, C.P. Sharma, Synthesis and evaluation of lauryl succinyl chitosan particles towards oral 773 
insulin delivery and absorption, J. Control. Release. 135 (2009) 144–151. 774 
doi:10.1016/j.jconrel.2009.01.011. 775 
[110] G. Sharma, K. Wilson, C.F. van der Walle, N. Sattar, J.R. Petrie, M.N. V Ravi Kumar, Microemulsions 776 
for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic 777 
rats, Eur. J. Pharm. Biopharm. 76 (2010) 159–69. doi:10.1016/j.ejpb.2010.07.002. 778 
[111] K. Sonaje, E.Y. Chuang, K.J. Lin, T.C. Yen, F.Y. Su, M.T. Tseng, H.W. Sung, Opening of epithelial tight 779 
junctions and enhancement of paracellular permeation by chitosan: Microscopic, ultrastructural, 780 
and computed-tomographic observations, Mol. Pharm. 9 (2012) 1271–1279. 781 
doi:10.1021/mp200572t. 782 
[112] T. Trenktrog, B.W. Müller, F.M. Specht, J. Seifert, Enteric coated insulin pellets: Development, drug 783 
release and in vivo evaluation, Eur. J. Pharm. Sci. 4 (1996) 323–329. doi:10.1016/0928-784 
0987(95)00162-X. 785 
[113] C.B. Woitiski, R.J. Neufeld, F. Veiga, R.A. Carvalho, I. V. Figueiredo, Pharmacological effect of orally 786 
delivered insulin facilitated by multilayered stable nanoparticles, Eur. J. Pharm. Sci. 41 (2010) 556–787 
563. doi:10.1016/j.ejps.2010.08.009. 788 
[114] C.Q. Xia, W.C. Shen, Tyrphostin-8 enhances transferrin receptor-mediated transcytosis in Caco-2 789 
cells and increases hypoglycemic effect of orally administered insulin-transferrin conjugate in 790 
diabetic rats, Pharm. Res. 18 (2001) 191–195. doi:10.1023/A:1011032502097. 791 
[115] Z. Al-Kurdi, B.Z. Chowdhry, S.A. Leharne, N.A. Qinna, M.M.H. Al-Omari, A.A. Badwan, Influence of 792 
glutathione on the bioactivity of subcutaneously or orally administered insulin to rats, Protein Pept. 793 
Lett. 22 (2015) 489–496. doi:0929-8665/15. 794 
[116] N.A. Qinna, Q.G. Karwi, N. Al-Jbour, M.A. Al-Remawi, T.M. Alhussainy, K.A. Al-So’ud, M.M.H. Al 795 
Omari, A.A. Badwan, Influence of molecular weight and degree of deacetylation of low molecular 796 
weight chitosan on the bioactivity of oral insulin preparations, Mar. Drugs. 13 (2015) 1710–1725. 797 
doi:10.3390/md13041710. 798 
[117] H. Guo, H. Li, J. Gao, G. Zhao, L. Ling, B. Wang, Q. Gui, Y. Gu, C. Li, Phenylboronic acid-based 799 
amphiphilic glycopolymeric nanocarriers for in vivo insulin delivery, Polym. Chem. 7 (2016) 3189–800 
3199. doi:10.1039/C6PY00131A. 801 
[118] J. Wang, M. Xu, X. Cheng, M. Kong, Y. Liu, C. Feng, X. Chen, Positive/negative surface charge of 802 
chitosan based nanogels and its potential influence on oral insulin delivery, Carbohydr. Polym. 136 803 
(2016) 867–874. doi:10.1016/j.carbpol.2015.09.103. 804 
[119] M. Jelvehgari, P.Z. Milani, M.R. Siahi-Shabad, F. Monajjemzadeh, A. Nokhodchi, Z. Azari, H. 805 
Valizadeh, In vitro and in vivo evaluation of insulin microspheres containing proteaseinhibitor, 806 
Arzneimittelforschung. 61 (2011) 14–22. 807 
[120] R.C. Mundargi, V. Rangaswamy, T.M. Aminabhavi, Poly(N-vinylcaprolactam-co-methacrylic acid) 808 
hydrogel microparticles for oral insulin delivery, J. Microencapsul. 28 (2011) 384–394. 809 
doi:10.3109/02652048.2011.576782. 810 
[121] E. Lee, J. Lee, S. Jon, A novel approach to oral delivery of insulin by conjugating with low molecular 811 
weight chitosan, Bioconjug. Chem. 21 (2010) 1720–1723. doi:10.1021/bc100093v. 812 
[122] B.Y. Kim, J.H. Jeong, K. Park, J.D. Kim, Bioadhesive interaction and hypoglycemic effect of insulin-813 
loaded lectin-microparticle conjugates in oral insulin delivery system, J. Control. Release. 102 (2005) 814 
525–538. doi:10.1016/j.jconrel.2004.10.032. 815 
[123] M. Liu, J. Zhang, X. Zhu, W. Shan, L. Li, J. Zhong, Z. Zhang, Y. Huang, Efficient mucus permeation and 816 
 33 
tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles 817 
for oral insulin delivery, J. Control. Release. 222 (2016) 67–77. doi:10.1016/j.jconrel.2015.12.008. 818 
[124] G. Sharma, C.F. Van Der Walle, M.N. V Ravi Kumar, Antacid co-encapsulated polyester nanoparticles 819 
for peroral delivery of insulin: Development, pharmacokinetics, biodistribution and 820 
pharmacodynamics, Int. J. Pharm. 440 (2013) 99–110. doi:10.1016/j.ijpharm.2011.12.038. 821 
[125] U. Ubaidulla, Y. Sultana, F.J. Ahmed, R.K. Khar, A.K. Panda, Chitosan phthalate microspheres for oral 822 
delivery of insulin: Preparation, characterization, and in vitro evaluation, Drug Deliv. 14 (2007) 19–823 
23. doi:10.1080/10717540600559478. 824 
[126] H.J. Cho, J. Oh, M.K. Choo, J.I. Ha, Y. Park, H.J. Maeng, Chondroitin sulfate-capped gold nanoparticles 825 
for the oral delivery of insulin, Int. J. Biol. Macromol. 63 (2014) 15–20. 826 
doi:10.1016/j.ijbiomac.2013.10.026. 827 
[127] D.R. Bhumkar, H.M. Joshi, M. Sastry, V.B. Pokharkar, Chitosan reduced gold nanoparticles as novel 828 
carriers for transmucosal delivery of insulin, Pharm. Res. 24 (2007) 1415–1426. doi:10.1007/s11095-829 
007-9257-9. 830 
[128] M. Cui, W. Wu, L. Hovgaard, Y. Lu, D. Chen, J. Qi, Liposomes containing cholesterol analogues of 831 
botanical origin as drug delivery systems to enhance the oral absorption of insulin, Int. J. Pharm. 489 832 
(2015) 277–284. doi:10.1016/j.ijpharm.2015.05.006. 833 
[129] D. Sakloetsakun, S. Dünnhaupt, J. Barthelmes, G. Perera, A. Bernkop-Schnürch, Combining two 834 
technologies: Multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for 835 
oral insulin administration, Int. J. Biol. Macromol. 61 (2013) 363–372. 836 
doi:10.1016/j.ijbiomac.2013.08.002. 837 
[130] A. Viehof, L. Javot, A. Béduneau, Y. Pellequer, A. Lamprecht, Oral insulin delivery in rats by 838 
nanoparticles prepared with non-toxic solvents, Int. J. Pharm. 443 (2013) 169–174. 839 
doi:10.1016/j.ijpharm.2013.01.017. 840 
[131] T.A. Sonia, M.R. Rekha, C.P. Sharma, Bioadhesive hydrophobic chitosan microparticles for oral 841 
delivery of insulin: In vitro characterization and in vivo uptake studies, J. Appl. Polym. Sci. 119 (2011) 842 
2902–2910. doi:10.1002/app.32979. 843 
[132] M. Alibolandi, F. Alabdollah, F. Sadeghi, M. Mohammadi, K. Abnous, M. Ramezani, F. Hadizadeh, 844 
Dextran-b-poly(lactide-co-glycolide) polymersome for oral delivery of insulin: In vitro and in vivo 845 
evaluation, J. Control. Release. 227 (2016) 58–70. doi:10.1016/j.jconrel.2016.02.031. 846 
[133] N. Zhang, Q. Ping, G. Huang, W. Xu, Y. Cheng, X. Han, Lectin-modified solid lipid nanoparticles as 847 
carriers for oral administration of insulin, Int. J. Pharm. 327 (2006) 153–159. 848 
doi:10.1016/j.ijpharm.2006.07.026. 849 
[134] E. Ma, H. Ma, Z. Liu, C. Zheng, M. Duan, In vitro and in vivo evaluation of a novel oral insulin 850 
formulation, Acta Pharmacol. Sin. 27 (2006) 1382–1388. doi:10.1111/j.1745-7245.2006.00424.x. 851 
[135] L.K. Tomar, C. Tyagi, S.S. Lahiri, H. Singh, Poly(PEGDMA-MAA) copolymeric micro and nanoparticles 852 
for oral insulin delivery, Polym. Adv. Technol. 22 (2011) 1760–1767. doi:10.1002/pat.1669. 853 
[136] Z. Li, J. Chen, W. Sun, Y. Xu, Investigation of archaeosomes as carriers for oral delivery of peptides, 854 
Biochem. Biophys. Res. Commun. 394 (2010) 412–417. doi:10.1016/j.bbrc.2010.03.041. 855 
[137] H. Sun, D. Liu, Y. Li, X. Tang, Y. Cong, Preparation and in vitro/ in vivo characterization of enteric-856 
coated nanoparticles loaded with the antihypertensive peptide VLPVPR, Int. J. Nanomedicine. 9 857 
(2014) 1709–1716. doi:10.2147/IJN.S56092. 858 
[138] S. Dünnhaupt, J. Barthelmes, J. Iqbal, G. Perera, C.C. Thurner, H. Friedl, A. Bernkop-Schnürch, In vivo 859 
evaluation of an oral drug delivery system for peptides based on S-protected thiolated chitosan, J. 860 
Control. Release. 160 (2012) 477–485. doi:10.1016/j.jconrel.2012.04.020. 861 
[139] H.L. Luessen, B.J. de Leeuw, M.W. Langemeÿer, A.B. de Boer, J.C. Verhoef, H.E. Junginger, 862 
Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the 863 
intestinal absorption of the peptide drug buserelin in vivo, Pharm. Res. 13 (1996) 1668–1672. 864 
doi:10.1023/A:1016488623022. 865 
[140] M. Wang, Y. Zhang, J. Feng, T. Gu, Q. Dong, X. Yang, Y. Sun, Y. Wu, Y. Chen, W. Kong, Preparation, 866 
 34 
characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-867 
glycolide) nanoparticles for intestinal delivery of exendin-4, Int. J. Nanomedicine. 8 (2013) 1141–868 
1154. doi:10.2147/IJN.S41457. 869 
[141] C. Chen, X. Zhu, Y. Dou, J. Xu, J. Zhang, T. Fan, J. Du, K. Liu, Y. Deng, L. Zhao, Y. Huang, Exendin-4 870 
loaded nanoparticles with a lipid shell and aqueous core containing micelles for enhanced intestinal 871 
absorption, J. Biomed. Nanotechnol. 11 (2015) 865–876. doi:10.1166/jbn.2015.1971. 872 
[142] Y.S. Youn, S.Y. Chae, S. Lee, M.J. Kwon, H.J. Shin, K.C. Lee, Improved peroral delivery of glucagon-like 873 
peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation, Eur. J. 874 
Pharm. Biopharm. 68 (2008) 667–75. doi:10.1016/j.ejpb.2007.07.009. 875 
[143] X. Li, C. Wang, R. Liang, F. Sun, Y. Shi, A. Wang, W. Liu, K. Sun, Y. Li, The glucose-lowering potential of 876 
exenatide delivered orally via goblet cell- targeting nanoparticles, Pharm. Res. 32 (2015) 1017–1027. 877 
doi:10.1007/s11095-014-1513-1. 878 
[144] S.Y. Chae, C. Jin, H.J. Shin, Y.S. Youn, S. Lee, K.C. Lee, Preparation, characterization, and application 879 
of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery, 880 
Bioconjugate Chem. 19 (2008) 334–341. doi:10.1021/bc700292v. 881 
[145] J.W. Joseph, J. Kalitsky, S. St-Pierre, P.L. Brubaker, Oral delivery of glucagon-like peptide-1 in a 882 
modified polymer preparation normalizes basal glycaemia in diabetic db/db mice, Diabetologia. 43 883 
(2000) 1319–28. doi:10.1007/s001250051529. 884 
[146] N. Shrestha, F. Araújo, M.-A. Shahbazi, E. Mäkilä, M.J. Gomes, M. Airavaara, E.I. Kauppinen, J. Raula, 885 
J. Salonen, J. Hirvonen, B. Sarmento, H.A. Santos, Oral hypoglycaemic effect of GLP-1 and DPP4 886 
inhibitor based nanocomposites in a diabetic animal model, J. Control. Release. 232 (2016) 113–119. 887 
doi:10.1016/j.jconrel.2016.04.024. 888 
[147] F. Araújo, N. Shrestha, M.A. Shahbazi, D. Liu, B. Herranz-Blanco, E.M. Mäkilä, J.J. Salonen, J.T. 889 
Hirvonen, P.L. Granja, B. Sarmento, H.A. Santos, Microfluidic assembly of a multifunctional tailorable 890 
composite system designed for site specific combined oral delivery of peptide drugs, ACS Nano. 9 891 
(2015) 8291–8302. doi:10.1021/acsnano.5b02762. 892 
[148] F.-Y. Su, E.-Y. Chuang, P.-Y. Lin, Y.-C. Chou, C.-T. Chen, F.-L. Mi, S.-P. Wey, T.-C. Yen, K.-J. Lin, H.-W. 893 
Sung, Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses 894 
of oral administration of G-CSF-containing nanoparticles, Biomaterials. 35 (2014) 3641–9. 895 
doi:10.1016/j.biomaterials.2014.01.020. 896 
[149] Z. Khatun, Nurunnabi, K.J. Cho, Y. Byun, Y.H. Bae, Y. Lee, Oral absorption mechanism and anti-897 
angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates, J. Control. Release. 177 898 
(2014) 64–73. doi:10.1016/j.jconrel.2013.12.034. 899 
[150] Y. Zheng, Y. Qiu, M.F. Lu, D. Hoffman, T.L. Reiland, Permeability and absorption of leuprolide from 900 
various intestinal regions in rabbits and rats, Int. J. Pharm. 185 (1999) 83–92. doi:10.1016/S0378-901 
5173(99)00146-5. 902 
[151] J. Iqbal, C. Vigl, G. Moser, M. Gasteiger, G. Perera, A. Bernkop-Schnürch, Development and in vivo 903 
evaluation of a new oral nanoparticulate dosage form for leuprolide based on polyacrylic acid, Drug 904 
Deliv. 18 (2011) 432–40. doi:10.3109/10717544.2011.577108. 905 
[152] P. Uhl, F. Helm, G. Hofhaus, S. Brings, C. Kaufman, K. Leotta, S. Urban, U. Haberkorn, W. Mier, G. 906 
Fricker, A liposomal formulation for the oral application of the investigational hepatitis B drug 907 
Myrcludex B, Eur. J. Pharm. Biopharm. 103 (2016) 159–166. doi:10.1016/j.ejpb.2016.03.031. 908 
[153] S.A. Moreno-Mendieta, D. Guillén, C. Espitia, R. Hernández-Pando, S. Sanchez, R. Rodríguez-Sanoja, 909 
A novel antigen-carrier system: the Mycobacterium tuberculosis Acr protein carried by raw starch 910 
microparticles, Int. J. Pharm. 474 (2014) 241–8. doi:10.1016/j.ijpharm.2014.07.041. 911 
[154] T.A.S. Aguirre, M. Rosa, I.S. Coulter, D.J. Brayden, In vitro and in vivo preclinical evaluation of a 912 
minisphere emulsion-based formulation (SmPill®) of salmon calcitonin, Eur. J. Pharm. Sci. 79 (2015) 913 
102–111. doi:10.1016/j.ejps.2015.09.001. 914 
[155] P.J. Sinko, Y.H. Lee, V. Makhey, G.D. Leesman, J.P. Sutyak, H. Yu, B. Perry, C.L. Smith, P. Hu, W.E. J, 915 
L.M. Falzone, L.T. McWhorter, J.P. Gilligan, W. Stern, Biopharmaceutical approaches for developing 916 
 35 
and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral 917 
absorption of salmon calcitonin (sCT), Pharm. Res. 16 (1999) 527–533. 918 
doi:10.1023/A:1018819012405. 919 
[156] V. Gupta, B.H. Hwang, N. Doshi, S. Mitragotri, A permeation enhancer for increasing transport of 920 
therapeutic macromolecules across the intestine, J. Control. Release. 172 (2013) 541–549. 921 
doi:10.1016/j.jconrel.2013.05.002. 922 
[157] V. Gupta, B.H. Hwang, J. Lee, A.C. Anselmo, N. Doshi, S. Mitragotri, Mucoadhesive intestinal devices 923 
for oral delivery of salmon calcitonin, J. Control. Release. 172 (2013) 753–762. 924 
doi:10.1016/j.jconrel.2013.09.004. 925 
[158] W.-P. Cheng, C. Thompson, S.M. Ryan, T. Aguirre, L. Tetley, D.J. Brayden, In vitro and in vivo 926 
characterisation of a novel peptide delivery system: amphiphilic polyelectrolyte-salmon calcitonin 927 
nanocomplexes, J. Control. Release. 147 (2010) 289–97. doi:10.1016/j.jconrel.2010.07.128. 928 
[159] M. Cetin, Y.S. Youn, Y. Capan, K.C. Lee, Preparation and characterization of salmon calcitonin-biotin 929 
conjugates, AAPS PharmSciTech. 9 (2008) 1191–7. doi:10.1208/s12249-008-9165-2. 930 
[160] D. Guggi, C.E. Kast, A. Bernkop-Schnürch, In vivo evaluation of an oral salmon calcitonin-delivery 931 
system based on a thiolated chitosan carrier matrix, Pharm. Res. 20 (2003) 1989–1994. doi:0724-932 
8741/03/1200-1989/0. 933 
[161] H.E. Lee, M.J. Lee, C.R. Park, A.Y. Kim, K.H. Chun, H.J. Hwang, D.H. Oh, S.O. Jeon, J.S. Kang, T.S. Jung, 934 
G.J. Choi, S. Lee, Preparation and characterization of salmon calcitonin–sodium triphosphate ionic 935 
complex for oral delivery, J. Control. Release. 143 (2010) 251–257. 936 
doi:10.1016/j.jconrel.2009.12.011. 937 
[162] A. Huang, A. Makhlof, Q. Ping, Y. Tozuka, H. Takeuchi, N-trimethyl chitosan-modified liposomes as 938 
carriers for oral delivery of salmon calcitonin, Drug Deliv. 18 (2011) 562–569. 939 
doi:10.3109/10717544.2011.596585. 940 
[163] A. Makhlof, M. Werle, Y. Tozuka, H. Takeuchi, A mucoadhesive nanoparticulate system for the 941 
simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa, J. 942 
Control. Release. 149 (2011) 81–88. doi:10.1016/j.jconrel.2010.02.001. 943 
[164] A. Makhlof, S. Fujimoto, Y. Tozuka, H. Takeuchi, In vitro and in vivo evaluation of WGA-carbopol 944 
modified liposomes as carriers for oral peptide delivery, Eur. J. Pharm. Biopharm. 77 (2011) 216–24. 945 
doi:10.1016/j.ejpb.2010.12.008. 946 
[165] M. Cetin, M.S. Aktas, I. Vural, M. Ozturk, Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA 947 
nanoparticles: In vitro and in vivo evaluation, J. Microencapsul. 29 (2012) 156–66. 948 
doi:10.3109/02652048.2011.635426. 949 
[166] M. Werle, H. Takeuchi, Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, 950 
characterisation and in vivo evaluation, Int. J. Pharm. 370 (2009) 26–32. 951 
doi:10.1016/j.ijpharm.2008.11.013. 952 
[167] N. Thirawong, J. Thongborisute, H. Takeuchi, P. Sriamornsak, Improved intestinal absorption of 953 
calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes, J. Control. Release. 954 
125 (2008) 236–45. doi:10.1016/j.jconrel.2007.10.023. 955 
[168] C. Prego, D. Torres, E. Fernandez-Megia, R. Novoa-Carballal, E. Quiñoá, M.J. Alonso, Chitosan-PEG 956 
nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree, J. 957 
Control. Release. 111 (2006) 299–308. doi:10.1016/j.jconrel.2005.12.015. 958 
[169] M. Garcia-Fuentes, C. Prego, D. Torres, M.J. Alonso, A comparative study of the potential of solid 959 
triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral 960 
calcitonin delivery, Eur. J. Pharm. Sci. 25 (2005) 133–43. doi:10.1016/j.ejps.2005.02.008. 961 
[170] K. Gradauer, J. Barthelmes, C. Vonach, G. Almer, H. Mangge, B. Teubl, E. Roblegg, S. Dünnhaupt, E. 962 
Fröhlich, A. Bernkop-Schnürch, R. Prassl, Liposomes coated with thiolated chitosan enhance oral 963 
peptide delivery to rats, J. Control. Release. 172 (2013) 872–878. doi:10.1016/j.jconrel.2013.10.011. 964 
[171] J. Manosroi, W. Lohcharoenkal, F. Götz, R.G. Werner, W. Manosroi, A. Manosroi, Novel application 965 
of polioviral capsid: development of a potent and prolonged oral calcitonin using polioviral binding 966 
 36 
ligand and Tat peptide, Drug Dev. Ind. Pharm. 40 (2014) 1092–100. 967 
doi:10.3109/03639045.2013.809533. 968 
[172] H.S. Yoo, T. Park, Biodegradable nanoparticles containing protein-fatty acid complexes for oral 969 
delivery of salmon calcitonin, J. Pharm. Sci. 93 (2004) 488–495. doi:10.1002/jps.10573. 970 
[173] I. Lozoya-Agullo, M. Zur, O. Wolk, A. Beig, I. González-Álvarez, M. González-Álvarez, M. Merino-971 
Sanjuán, M. Bermejo, A. Dahan, In-situ intestinal rat perfusions for human Fabs prediction and BCS 972 
permeability class determination: Investigation of the single-pass vs. the Doluisio experimental 973 
approaches, Int. J. Pharm. 480 (2015) 1–7. doi:10.1016/j.ijpharm.2015.01.014. 974 
[174] I. Lozoya-Agullo, M. Zur, A. Beig, N. Fine, Y. Cohen, M. González-Álvarez, M. Merino-Sanjuán, I. 975 
González-Álvarez, M. Bermejo, A. Dahan, Segmental-dependent permeability throughout the small 976 
intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat 977 
perfusion, Int. J. Pharm. 515 (2016) 201–208. doi:10.1016/j.ijpharm.2016.09.061. 978 
[175] U. Fagerholm, M. Johansson, H. Lennernäs, Comparison between permeability coefficients in rat and 979 
human jejunum, Pharm. Res. 13 (1996) 1336–1342. doi:10.1023/A:1016065715308. 980 
[176] X. Cao, S.T. Gibbs, L. Fang, H.A. Miller, C.P. Landowski, H.C. Shin, H. Lennernas, Y. Zhong, G.L. 981 
Amidon, L.X. Yu, D. Sun, Why is it challenging to predict intestinal drug absorption and oral 982 
bioavailability in human using rat model, Pharm. Res. 23 (2006) 1675–1686. doi:10.1007/s11095-983 
006-9041-2. 984 
[177] M.A. Lopes, B.A. Abrahim, L.M. Cabral, C.R. Rodrigues, R.M.F. Seiça, F.J. de Baptista Veiga, A.J. 985 
Ribeiro, Intestinal absorption of insulin nanoparticles: Contribution of M cells, Nanomedicine 986 
Nanotechnology, Biol. Med. 10 (2014) 1139–1151. doi:10.1016/j.nano.2014.02.014. 987 
[178] H.J. Van Kruiningen, A.B. West, B.J. Freda, K.A. Holmes, Distribution of Peyer’s patches in the distal 988 
ileum, Inflamm. Bowel Dis. 8 (2002) 180–185. doi:10.1097/00054725-200205000-00004. 989 
[179] H. Lennernäs, Regional intestinal drug permeation: Biopharmaceutics and drug development, Eur. J. 990 
Pharm. Sci. 57 (2014) 333–341. doi:10.1016/j.ejps.2013.08.025. 991 
[180] H. Lennernäs, S. Nylander, A.-L. Ungell, Jejunal permeability: A comparision between Ussing 992 
chambers and in humans, Pharm. Res. 14 (1997) 667–671. 993 
[181] P. Zhang, Y. Xu, X. Zhu, Y. Huang, Goblet cell targeting nanoparticle containing drug-loaded micelle 994 
cores for oral delivery of insulin, Int. J. Pharm. 496 (2015) 993–1005. 995 
doi:10.1016/j.ijpharm.2015.10.078. 996 
[182] W.H. Barr, S. Riegelman, Intestinal drug absorption and metabolism I: Comparison of methods and 997 
models to study physiological factors of in vitro and in vivo intestinal absorption, J. Pharm. Sci. 59 998 
(1970) 154–163. doi:10.1002/jps.2600590204. 999 
[183] A. Jain, S.K. Jain, l-Valine appended PLGA nanoparticles for oral insulin delivery, Acta Diabetol. 1000 
(2015) 663–676. doi:10.1007/s00592-015-0714-3. 1001 
[184] H. van de Waterbeemd, E. Gifford, ADMET in silico modelling: towards prediction paradise?, Nat. 1002 
Rev. Drug Discov. 2 (2003) 192–204. doi:10.1038/nrd1032. 1003 
[185] S.H. Welling, L.K.H. Clemmensen, S.T. Buckley, L. Hovgaard, P.B. Brockhoff, H.H.F. Refsgaard, In silico 1004 
modelling of permeation enhancement potency in Caco-2 monolayers based on molecular 1005 
descriptors and random forest, Eur. J. Pharm. Biopharm. 94 (2015) 152–159. 1006 
doi:10.1016/j.ejpb.2015.05.012. 1007 
[186] E. Sjögren, H. Thörn, C. Tannergren, In silico modeling of gastrointestinal drug absorption: predictive 1008 
performance of three physiologically based absorption models, Mol. Pharm. (2016). 1009 
doi:10.1021/acs.molpharmaceut.5b00861. 1010 
[187] W. Jiang, S. Kim, X. Zhang, R.A. Lionberger, B.M. Davit, D.P. Conner, L.X. Yu, The role of predictive 1011 
biopharmaceutical modeling and simulation in drug development and regulatory evaluation, Int. J. 1012 
Pharm. 418 (2011) 151–160. doi:10.1016/j.ijpharm.2011.07.024. 1013 
[188] A. Dokoumetzidisa, P. Macheras, IVIVC of controlled release formulations: Physiological–dynamical 1014 
reasons for their failure, J. Control. Release. 129 (2008) 76–78. doi:10.1016/j.jconrel.2008.04.005. 1015 
[189] E.L. McConnell, A.W. Basit, S. Murdan, Measurements of rat and mouse gastrointestinal pH, fluid 1016 
 37 
and lymphoid tissue, and implications for in-vivo experiments, J. Pharm. Pharmacol. 60 (2008) 63–1017 
70. doi:10.1211/jpp.60.1.0008. 1018 
[190] A.J.F. King, The use of animal models in diabetes research, Br. J. Pharmacol. 166 (2012) 877–894. 1019 
doi:10.1111/j.1476-5381.2012.01911.x. 1020 
[191] S.J. Morgan, C.S. Elangbam, S. Berens, E. Janovitz, A. Vitsky, T. Zabka, L. Conour, Use of animal 1021 
models of human disease for nonclinical safety assessment of novel pharmaceuticals, Toxicol. 1022 
Pathol. 0 (2012) 1–11. doi:10.1177/0192623312457273. 1023 
[192] B.O. Roep, M. Atkinson, M. von Herrath, Satisfaction (not) guaranteed: re-evaluating the use of 1024 
animal models of type 1 diabetes, Nat Rev Immunol. 4 (2004) 989–997. 10.1038/nri1502. 1025 
[193] T.S. Fröde, Y.S. Medeiros, Animal models to test drugs with potential antidiabetic activity, J. 1026 
Ethnopharmacol. 115 (2008) 173–183. doi:10.1016/j.jep.2007.10.038. 1027 
[194] M. a Valentovic, N. Alejandro, A. Betts Carpenter, P.I. Brown, K. Ramos, Streptozotocin (STZ) 1028 
diabetes enhances benzo(alpha)pyrene induced renal injury in Sprague Dawley rats, Toxicol. Lett. 1029 
164 (2006) 214–20. doi:10.1016/j.toxlet.2005.12.009. 1030 
[195] Y.-C. Lei, J.-S. Hwang, C.-C. Chan, C.-T. Lee, T.-J. Cheng, Enhanced oxidative stress and endothelial 1031 
dysfunction in streptozotocin-diabetic rats exposed to fine particles, Environ. Res. 99 (2005) 335–43. 1032 
doi:10.1016/j.envres.2005.03.011. 1033 
[196] F. Franconi, G. Seghieri, S. Canu, E. Straface, I. Campesi, W. Malorni, Are the available experimental 1034 
models of type 2 diabetes appropriate for a gender perspective?, Pharmacol. Res. 57 (2008) 6–18. 1035 
doi:10.1016/j.phrs.2007.11.007. 1036 
[197] J.L. Bussiere, P. Martin, M. Horner, J. Couch, M. Flaherty, L. Andrews, J. Beyer, C. Horvath, 1037 
Alternative strategies for toxicity testing of species-specific biopharmaceuticals, Int. J. Toxicol. 28 1038 
(2009) 230–53. doi:10.1177/1091581809337262. 1039 
[198] D.K. Badyal, H. Lata, A.P. Dadhich, Animal models of hypertension and effect of drugs, Indian J. 1040 
Pharmacol. 35 (2003) 349–362. doi:10.1155/2015/528757. 1041 
[199] J.A. Auer, A. Goodship, S. Arnoczky, S. Pearce, J. Price, L. Claes, B. von Rechenberg, M. Hofmann-1042 
Amtenbrinck, E. Schneider, R. Müller-Terpitz, F. Thiele, K.-P. Rippe, D.W. Grainger, Refining animal 1043 
models in fracture research: seeking consensus in optimising both animal welfare and scientific 1044 
validity for appropriate biomedical use., BMC Musculoskelet. Disord. 8 (2007) 72. doi:10.1186/1471-1045 
2474-8-72. 1046 
[200] L. Pénicaud, P. Ferré, J. Kande, A. Leturque, T. Issad, J. Girard, Effect of anesthesia on glucose 1047 
production and utilization in rats, Am. J. Physiol. - Endocrinol. Metab. 252 (1987) E365–E369. 1048 
doi:10.1172/JCI111133. 1049 
[201] P. V Turner, T. Brabb, C. Pekow, M.A. Vasbinder, Administration of substances to laboratory animals: 1050 
routes of administration and factors to consider, J. Am. Assoc. Lab. Anim. Sci. 50 (2011) 600–613. 1051 
[202] A.F. Hoggatt, J. Hoggatt, M. Honerlaw, L.M. Pelus, A spoonful of sugar helps the medicine go down: 1052 
a novel technique to improve oral gavage in mice, J. Am. Assoc. Lab. Anim. Sci. 49 (2010) 329–334. 1053 
[203] K. Õkva, E. Tamoševičiute, A. Čižiute, P. Pokk, O. Rukšenas, T. Nevalainen, Refinements for 1054 
intragastric gavage in rats, Scand. J. Lab. Anim. Sci. 33 (2006) 243–252. 1055 
[204] M. Bonnichsen, N. Dragsted, A.K. Hansen, The welfare impact of gavaging laboratory rats, Anim. 1056 
Welf. 14 (2005) 223–227. 1057 
[205] S. Saphier, A. Rosner, R. Brandeis, Y. Karton, Gastro intestinal tracking and gastric emptying of solid 1058 
dosage forms in rats using X-ray imagining, Int. J. Pharm. 388 (2010) 190–195. 1059 
doi:10.1016/j.ijpharm.2010.01.001. 1060 
[206] W.P. Norred, A simple method for intragastric administration of powdered materials to rats, Lab. 1061 
Anim. Sci. 33 (1983) 585–586. 1062 
[207] P. V Turner, C. Pekow, M.A. Vasbinder, T. Brabb, Administration of substances to laboratory animals: 1063 
equipment considerations, vehicle selection, and solute preparation, J. Am. Assoc. Lab. Anim. Sci. 50 1064 
(2011) 614–27. 1065 
[208] S. Parasuraman, R. Raveendran, R. Kesavan, Blood sample collection in small laboratory animals, J. 1066 
 38 
Pharmacol. Pharmacother. 1 (2010) 87. doi:10.4103/0976-500X.72350. 1067 
[209] S. Harloff-Helleberg, L.A.L. Fliervoet, M. Fanø, M. Schmitt, M. Antopolski, A. Urrti, H.M. Nielsen, 1068 
Biophysical characterization and in vivo evaluation of sucrose ester-based gels as carriers for oral 1069 
delivery of biopharmaceuticals, Submitted. (2016). 1070 
[210] Q. Jin, L. Feng, D.D. Wang, J.J. Wu, J. Hou, Z.R. Dai, S.G. Sun, J.Y. Wang, G.B. Ge, J.N. Cui, L. Yang, A 1071 
highly selective near-infrared fluorescent probe for carboxylesterase 2 and its bioimaging 1072 
applications in living cells and animals, Biosens. Bioelectron. 83 (2016) 193–199. 1073 
doi:10.1016/j.bios.2016.04.075. 1074 
 1075 
  1076 
 39 
Captions 1077 
 1078 
Figure 1: Graphic showing the in vivo barriers in the intestine following oral administration. 1079 
 1080 
Figure 2: Overview of methods used to evaluate oral bioavailability of insulin (A) and other 1081 
biopharmaceuticals (B) in vivo, ex vivo and in situ based on reviewed papers listed in Table 1 and 2. 1082 
 1083 
Figure 3: Overview of species used to evaluate oral bioavailability of insulin (A) and other 1084 
biopharmaceuticals (B) in vivo, in situ or ex vivo. The data are based on reviewed papers, listed in Table 1 1085 
and 2.   1086 
 1087 
Figure 4: Effect of anesthesia on blood glucose level in healthy rats after subcutaneous (SC) dosing of 1088 
insulin. The black arrows indicate momentary inhalation of isoflurane. The curves represent the average of 1089 
three rats ± SEM, except for the negative control where n=1. Blood samples were collected via the 1090 
sublingual tongue vein. 1091 
 1092 
Figure 5: Overview of sampling methods used to evaluate oral bioavailability of insulin (A) and other 1093 
biopharmaceuticals (B) following in vivo, in situ or ex vivo studies. The graphs are based on the reviewed 1094 
papers listed in Table 1 and 2.  1095 
 1096 
Figure 6: Overview of the analytical methods used to evaluate oral bioavailability of insulin (A) and other 1097 
biopharmaceuticals (B) in vivo, in situ or ex vivo. This is based on the reviewed papers listed in Table 1 and 1098 
2. 1099 
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